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CHAPTER 2 
 
FIGURE 1.  Kaplan–Meier survival curve generated with survival time 
calculated from the date of introduction into propagation tank until date 
of death by necrotizing hepatopancreatitis (NHP). Shrimp that were 
removed or died of causes other than NHP were censored at the time 
time of loss. 
 
FIGURE 2. Kaplan–Meier survival curve generated with survival time 
calculated from the date of introduction into propagation tank until date 
of death by necrotizing hepatopancreatitis (NHP) following addition of 
the control tank.  Shrimp removed for experimental studies or that died 
of causes other than NHP were censored at the time of loss. 
 
CHAPTER 3 
 
FIGURE 1. Shrimp survival post challenge with serial dilutions of a 
stock viral clarification (containing ~3.2 x 105 IMNV copy numbers/µL 
RNA) of infectious myonecrosis virus. Shrimp weighing 8-10 grams 
were injected with 100 µL of clarification into the third abdominal 
segment. n=20 shrimp for each viral challenge dose administered. 
 
FIGURE 2.  Diagram of the IMNV genome transcription and 
translation products (modified from Nibert (2007) Journal of General 
Virology) showing regions targeted for RNAi.   Predicted protein 
products are indicated by dark gray lines (Proteins 1-3) or gray shading 
(major capsid protein and RNA-dependent RNA polymerase).   Target 
regions for dsRNA production are indicated as thick black lines with 
corresponding nucleotide regions.  Longer length dsRNAs that were 
generated to Protein 1 and 2 encoding sequence included two iterations 
truncated by ~100 bp on either side (193-475 and 95-376).  Shorter 
dsRNAs generated within the Protein 1 encoding region are magnified 
(bottom left). 
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FIGURE 3.  Shrimp survival post-administration of candidate antiviral 
dsRNAs corresponding to virus gene targets and post-infection with 
IMNV.  Animals were inoculated with 2.0 µg dsRNA at day 0, then 
challenged with virus 2 days later.  Positive control animals received an 
inoculation containing an equivalent volume of RNase free water at day 
0.  Negative control animals received an equivalent volume of 2% 
saline (viral diluent) on day 2. The dsRNA target position on the IMNV 
genome or heterologous dsRNA (eGFP) is indicated (see Figure 2).  
Animal survival (displayed as a percent of the total animals per study 
group, y-axis)) was monitored daily after dsRNA administration (x-
axis).  3 replicates of 20 animals (n=60) weighing 5-7 grams were used 
for each treatment group.  
 
FIGURE 4. Quantitative Reverse Transcription Polymerase Chain 
Reaction (qRT-PCR) analysis of virus load in muscle tissue of animals 
subjected to candidate antiviral dsRNAs and IMNV infection, at 9-12 
days post-challenge.  dsRNA inoculated groups are underlined and 
numbers indicate the target position on the IMNV genome. The y-axis 
indicates log viral genome copy number calculated from an RNA 
standard curve generated per Andrade et al 2007.  Bars represent 
standard error within the sample. 
 
FIGURE 5. Shrimp survival was monitored post-administration of 
serial dilutions of dsRNA 95-475 (A) or dsRNA 3764-4805 (B) and 
after infection with IMNV.  Animals were inoculated with 2.0 µg, 0.2 
µg, or 0.02 µg dsRNA at day 0 and were challenged at day 10. Control 
animals (C) were injected at day 0 with dsRNA to eGFP, or an 
equivalent volume of RNAse free water (positive control), or with an 
equivalent volume of 2% saline at day 10 (negative control) prior to 
IMNV infection.  Animals were inoculated with 2.0 µg dsRNA at day 0 
and were challenged at day 10. D) Survival of all treatment groups at 
termination of study (Day 40).  Positive control animals received an 
inoculation containing an equivalent volume of RNase free water at day 
0.  Overall mortality at the termination of this experiment is shown in 
D) for which y-axis indicates the percent of survivors at day 40. 10 
animals with weights of 3-5 grams were used for each treatment 
(n=10). 
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FIGURE 6.  Shrimp survival was monitored post-administration with 
successive truncations of the initial dsRNA targeted to the Protein 1 
and 2 encoding regions of the genome (see Figure 2).  Animals were 
inoculated with 0.02 µg dsRNA at day 0 and infected with IMNV at 
day 10. X-axis indicates days post dsRNA administration.  A) Shrimp 
survival after administration of dsRNAs greater than 200 bp, including 
dsRNA 95-475, 193-475, and 95-376, followed by IMNV infection. B) 
Shrimp survival post-administration of dsRNAs less than 200 bp, 
including dsRNA 223-376, 194-275, or 219-273 and post-IMNV 
infection. C) Survival of positive or negative control animals and post-
IMNV infection. Positive control animals were inoculated with an 
equivalent volume of RNase free water at day 0 and negative control 
animals received an equivalent volume of 2% saline (viral diluent) on 
day 10.  D) Overall mortality (expressed as % survivors) at the 
termination of this experiment is shown for each of the dsRNAs 
(indicated according to fragment length).  Three replicate tanks of 10 
animals weighing 3-5 grams were used for each treatment (n=30) 
except the negative control for which there was a single tank (n=10). 
 
CHAPTER 4 
 
FIGURE 1. Percent survivorship of animals that were infected with 
a lethal dose of IMNV (day 0), then injected with dsRNA194-275 at 48 
h post-challenge.  Animals were observed for 20 days post-infection.  
n=30 animals with 3 replicate tanks of 10 animals per treatment. 
 
FIGURE 2. Virus copy number, as determined by quantitative RT-
PCR, in muscle tissue from IMNV-infected L. vannamei that were 
provided with dsRNA treatment or control conditions.   Muscle issues 
were collected from dsRNA194-275 survivors (Survivors) that 
survived and were sacrificed at day 20 post challenge.  For the dsRNA 
194-275 Mortalities, Sham, and dseGFP groups, samples were 
collected from dead or moribund animals from day 9-14 post 
challenge. Y-axis indicates mean log viral copy number calculated on 
The y-axis indicates log viral genome copy number calculated from an 
RNA standard curve generated per (Andrade et al 2007).  Bars 
represent standard error within the sample. n=6 animals per group 
 
FIGURE 3.  Percent survivorship of animals following injection 
challenge with IMNV inoculum and treatment by injection of dsRNA 
after 24 hours.  X-axis is days post challenge.  Y-axis is percent of 
animals surviving.  Sham animals received an equivalent dose of 
RNase free water and negative control animals were sham challenged 
with an equivalent dose of sterile 2% NaCl. 
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FIGURE 4.  Percent survivorship of animals following injection 
challenge with IMNV inoculum and treatment by injection of dsRNA 
after 48 hours.  X-axis is days post challenge.  Y-axis is percent of 
animals surviving.  Sham animals received an equivalent dose of 
RNase free water and negative control animals were sham challenged 
with an equivalent dose of sterile 2% NaCl. 
   
FIGURE 5.   Percent survivorship of animals following injection 
challenge with IMNV inoculum and treatment by injection of dsRNA 
after 72 hours.  X-axis is days post challenge.  Y-axis is percent of 
animals surviving.  Sham animals received an equivalent dose of 
RNase free water and negative control animals were sham challenged 
with an equivalent dose of sterile 2% NaCl. 
 
FIGURE 6.  Images of gross lesions of the same shrimp abdomen taken 
on day 4 post challenge (Left) and day 12 post challenge (Right).  Focal 
to multifocal muscle opacities were observed 4 d post challenge and 2 
days post dsRNA194-275 administration.  Gross lesions were not 
apparent in animals administered dsRNA at 12 days post challenge and 
10 days post dsRNA administration 
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CHAPTER 1: GENERAL INTRODUCTION 
Introduction 
Aquaculture has become one of the most rapidly growing sources of food animal 
protein in the world.  Decreasing stocks within wild fisheries and increasing demand for 
seafood are driving this precipitous growth mostly from the United States, Europe, and 
Japan.  More recently demand in developing economies has grown at a rapid pace.  One 
of the fastest growing market segments within aquaculture is farm-raised shrimp.  
According to data from the United Nations Food and Agriculture Organization (FAO), 
the last twenty years has seen farmed shrimp production of Litopenaeus vannamei, 
commonly known as the Pacific white shrimp or the whiteleg shrimp, rise from 8000 
metric tons produced in 1980 to 1,380,000 metric tons produced in 2004.13 Most of this 
rapid increase in production can be accounted for by growth in culture throughout 
Southeast Asia, as these countries began to intensively culture imported L. vannamei in 
lieu of the native Penaeus monodon, the black tiger shrimp, for export. Countries with 
rapid growth of L. vannamei production include countries such as China, Thailand, 
Indonesia, and Vietnam.13   Domesticated stocks of L. vannamei, a species native to the 
west coast of South and Central America, were perfectly suited to culture conditions in 
Asia.  L. vannamei proved to be faster growing, more adaptable to pond conditions, had 
less stringent dietary requirements, and most importantly, was amenable to much higher 
stocking densities. The culture of farm-raised shrimp for export to the US and Europe 
provide a very important source of foreign currencies for many of these developing 
countries and thus, expansion of the industry was pursued quite rapidly.56 
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 Following the introduction of exotic L. vannamei into Asia as the first 
domesticated shrimp species, it rapidly became the dominant species worldwide, where 
in 2004 it accounted for half of the farm raised shrimp produced globally.24 
Subsequently, demand in the United States and the European Union rose as a more 
affordable shrimp came onto the market.    For example, shrimp imports rose from $1.6 
billion to $3.7 billion from 1990-200452 representing 34% of total seafood imports and 
25% of total seafood consumption in 2004.  As of 2004, 70% of the United States 
seafood was imported with 40% of it being farm-raised in origin.52 Rapidly expanding 
production of L. vannamei outstripped demand and led to price depression in 
international markets, mostly in the United States and European Union. Farm gate value 
for 15–20 gram size L. vannamei has steadily decreased from $5 in 2000 to about $3 in 
2005.13 Per capita consumption of seafood products by consumers has also seen a strong 
increase over this time period.  In 2006, the average per capita consumption of seafood in 
the United States was 16.5 pounds, with 4.4 pounds of this consisting of shrimp.4 Current 
consumer demand for seafood has remained high with per capita consumption of shrimp 
being 4.1 pounds per year in 2009, all while per capita consumption of all other levels of 
animal protein in the United States have been in decline, with total consumption dropping 
in a six year period from 237 pounds in 2004 to 224 pounds in 2010.33 
As farm-raised shrimp production of L. vannamei has increased in market share 
and industry size, the impact of disease on production and profitability has also increased.  
Producers have adopted practices such as higher stocking densities, smaller inland lined 
pond culture, and higher feeding rates using genetically selected animals for higher 
growth to increase competitiveness and increase production.   This increase in intensity, 
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and thus higher stocking densitities has led to an increasing vulnerability to infectious 
diseases, specifically viral pathogens and bacterial infections.55 In addition, such a new 
and rapidly growing industry in developing economies often does not have the regulatory 
apparatuses in place to prevent importation of new infectious diseases with stocks of live 
animals.  For example, pathogen translocation and disease outbreaks have ensued with 
significant economic losses immediately following the emergence of each of the major 
viral pathogens55 often crossing global hemispheres in a very short period of time.  
Infectious diseases caused by viral pathogens can cause substantial mortality in L. 
vannamei and result in devastating financial losses.  It has been estimated that annual 
global losses, mostly viral in etiology, have been as high as $3 billion a year.27,56 The 
impact of disease as an impediment to growth in this new production system and species 
cannot be understated and thus, novel research that may mitigate these disease losses or 
assist in disease prevention is crucial.   
The objectives of the research described within this dissertation are focused on 
developing disease models and model systems for viral and bacterial pathogens in the 
commercially important, farm-raised marine shrimp species, L. vannamei.  Following the 
establishment of these models is the development and evaluation of RNA interference 
(RNAi) based technology for use as both a prophylactic and therapeutic intervention 
against disease.  In other words, could a scientific approach be used to model relevant 
infections with different pathogenic organisms in this species?  Can these models then be 
used as a foundation to develop antiviral prophylaxis or therapeutics based upon a newly 
described RNAi based specific immune response? 
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The first paper describes the development of a propagation system for use in 
conjunction with a challenge model for a bacterial pathogen, the Necrotizing 
Hepatopancreatitis Bacterium (NHPB).  This paper provides the foundations for 
conducting experimental challenge studies using an obligate intracellular bacterium that 
cannot be cultured in vitro and therefore must be propagated in vivo.   
The second paper describes the development of a viral disease challenge model 
using a newly emerged viral pathogen, Infectious Myonecrosis Virus (IMNV), as well as 
the use of RNAi based antiviral molecules to prevent mortality caused by this disease.   It 
also describes a novel method to optimize an RNAi antiviral molecule by down-selection 
of sequences in order to elucidate the minimum requirement for a successful RNAi 
antiviral.  Additionally, this manuscript evaluates the dosage requirements and duration 
of the protective response observed using a down-selected RNAi antiviral molecule. 
 Finally, the third paper examines the application of these aforementioned down-
selected RNAi antiviral molecules as a therapeutic treatment against preexisting IMNV 
infection.  The objective of this work was to ascertain if these triggers could not only 
prevent disease, but also be used as a therapeutic treatment which may have application 
in the field during an acute outbreak or latent infection within a pond system.   
Dissertation Organization 
This dissertation is organized in a journal paper format. Chapter 1 includes a brief  
introduction to the topic followed by a review of the literature, with a focus on current 
knowledge of the modeled disease organisms and disease intervention strategies being 
evaluated and explored in shrimp infectious disease research. Chapters 2, 3, and 4 are the 
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author’s research projects prepared in manuscript format for publication. John Dustin Loy 
was the primary researcher and author of all manuscripts with assistance from the co-
authors as listed. Chapter 5 contains the general conclusions and implications of the 
conducted research followed by an acknowledgments section. 
Literature Review 
White Spot Syndrome Virus: The first shrimp disease pandemic 
White spot syndrome virus (WSSV) was one of the first economically significant 
diseases in shrimp production to emerge and become pandemic, resulting in worldwide 
losses in the billions of dollars.  WSSV was first observed in 1992 after several outbreaks 
of a high mortality disease of viral origin in cultured Penaeus japonicus occurred in 
northern Taiwan.   In 1993 the disease was seen in the black tiger prawn, P. monodon.6 
This disease quickly spread across the Asian continent having a tremendous impact on 
the shrimp industry.  It is estimated that Asia alone has lost over $6 billion in production 
since 1992.   Following the introduction of WSSV into the Americas (Ecuador) in 1999, 
it accounted for losses of $1-2 billion in a few years time.27 This disease translocation 
was devastating to the shrimp industries in countries with high levels of shrimp culture.  
For example, Ecuador alone experienced dramatic losses with a 65% loss in production 
observed immediately after the introduction of WSSV into the country.  This accounts 
for, in lost exports alone, over $500 million.  In addition, 130,000 jobs were lost and over 
100,000 hectares of ponds were left abandoned as WSSV made it impossible to profitably 
culture shrimp.32 Similarly, Peru experienced a precipitous drop in production to one 
tenth of the production levels seen in 1998, just two years following the introduction of 
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WSSV.  In Peru in 2000, 85% of shrimp ponds had been abandoned as producers had 
accumulated $9 million in lost feed costs.32 In China, it was estimated that 80% of total 
production losses annually were and continue to be attributed to WSSV outbreaks.64 The 
vast majority of these losses occur because a pathogenic virus in a pond of growing 
shrimp forces the grower to flush out a stocked pond, prematurely harvest (if the animals 
are marketable), and increase production costs through decreased feed conversion.  
Moreover, this can be a complete loss of animals from mortality if the disease is not 
diagnosed rapidly.55   
Necrotizing Hepatopancreatitis: and emerging bacterial pathogen 
In addition to viral diseases, diseases with bacterial etiology remain a serious 
concern for shrimp farmers.   However, often these disease problems exist as secondary 
infections in healthy animals or are food safety issues, such as observed infections or 
colonization with Vibrio sp.  Few primary bacterial pathogens have been characterized or 
described in shrimp. However, at least one primary pathogen has been found to be 
associated with disease in cultured L. vannamei, called necrotizing hepatopancreatitis 
bacterium (NHPB).  The syndrome caused by NHPB, necrotizing hepatopancreatitis 
(NHP) was first reported on a shrimp farm in Texas in 1985 and has since been 
demonstrated in cultured shrimp in Peru, Ecuador, Venezuela, Brazil, Panama, Costa 
Rica, and Mexico where it has caused significant mortalities in affected ponds.9,25,28    
NHPB is a gram-negative, pleomorphic, obligate intracellular bacterium.15 
Phylogenetic analysis of 16S rRNA has placed it in the α-subclass of Proteobacteria, 
along with such pathogens as Rickettsia (~83.5% nucleotide identity).29 Clinical signs of 
infection include a reduction in feed intake and empty guts, softened shells, flaccid 
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muscle tissue, epicommensal fouling, darkened gills and pleopods, and atrophy of the 
hepatopancreas organ.25 The hepatopancreas organ is the primary site of infection for 
NHPB, and as such it undergoes changes over the course of infection.  In severe NHPB 
infection, the hepatopancreas may develop gross black streaks indicating the 
melanization of hepatopancreatic tubules. However, few, if any, of these gross lesions are 
pathopneumonic for NHP, making confirmatory testing by more specific molecular or 
immunologic tests such as Polymerase Chain Reaction (PCR) or immunohistochemistry 
prudent.  Histopathological characteristics of NHPB infection include hepatopancreatic 
atrophy and multifocal granulomatous lesions.  Lipids in resorptive (R) cells are reduced 
and the number of blister-like (B) cells is drastically reduced or absent in the 
hepatopancreatic tubules.  Cells present in the granulomatous lesion may be 
hypertrophied and contain masses of pale, basophilic non-membrane bound NHP-bacteria 
free in the cytoplasm. Secondary Vibrio infections, have been observed in some severe 
NHPB infections, complicating disease diagnosis and obscuring the primary cause of 
disease.25 
NHPB causes a disease in shrimp characterized by a 2-6 week incubation period 
followed by high mortality that peaks at approximately 34 days post exposure.54   In 
experimental infections using individual exposures of L. vannamei, Vincent and Lotz54 
observed stage I at 6 to 23 d post-exposure, stage II at 16 to 37 d post-exposure, and stage 
III at 16 to 51 d post-exposure.  The timing of stage III of NHP disease corresponded to 
observed mortalities from infection.54 Further work examining the time course of NHP 
disease, modeling of pond conditions favoring the disease, and development of an in vivo 
propagation method is further discussed in Chapter 2 of this dissertation.   
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 Although this agent is currently restricted to the Americas, the opportunity for 
worldwide spread of NHPB is high.  Frozen whole shrimp may provide a means for 
spread, as it is possible to propagate infections via frozen tissue7.  In addition, concerns 
over antibiotic residues have resulted in disuse of antibiotics in many areas, the only 
available intervention for NHPB.  Currently, little is understood about the life cycle or 
etiology of NHPB outside the shrimp host and more research into this area could help 
guide a prevention and control program in infected regions.     
Disease Prevention and Control in farm systems 
The very high risk, or potential risk, for tremendous losses associated with a 
disease outbreak has led to the development of various control strategies. The most 
important of these has been the utilization of a concept called “stock control.”  Stock 
control in shrimp production has been defined by Dr. Donald Lightner as “the use of 
captive or domesticated stocks, cultured under controlled conditions, and which have 
been the subject of an active disease surveillance and control program.”24   Although this 
practice is quite common among commercial operations in a variety of other farm-raised 
species, stock control was not initially pursued aggressively in shrimp culture.  This may 
be because traditional shrimp culture methods, practiced in many countries, relied on 
wild seed or post larvae to stock the ponds, and farmers felt little need to adopt these 
practices without cause.   
 Once a controlled culture system with disease free stocks is in place, other 
disease control practices focus largely on pathogen exclusion by stocking specific 
pathogen free (SPF) larvae or postlarvae, decontamination and filtration of water to 
prevent pathogen, pathogen vectors, or wild shrimp introduction, and strict biosecurity at 
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the hatchery and pond sites.24 These control strategies can be effective as long as virus 
remains excluded from the culture system.   However, this has become challenging due to 
the prevalence of WSSV and other significant pathogens that have become endemic in 
wild or extensively managed shrimp species in the estuarine waters surrounding shrimp 
farms as well as the heavy use of live feeds in broodstock maturation diets.  
 Viral outbreaks also cause devastating financial losses due to such acute 
mortality in these naïve susceptible SPF populations.  Complicating matters, viruses can 
also manifest as a low-level persistent infection without clinical signs in healthy animals, 
but stress or lower temperatures can trigger disease and mass mortalities.56   Without 
robust and vigilant diagnostics the disease can become widespread on pond sites and 
farms resulting in the potential for massive losses of animals in a short period of time.   
Currently, there are no truly effective interventions or therapeutic treatments for viral 
disease in shrimp farms, though some have shown promise experimentally10 and are 
described in detail later in this review.  
Following on the WSSV pandemic of the early 1990s in Asia and late 1990s in 
the Americas, the theme of a newly emerging disease causing massive untreatable losses 
and being spread across the globe continues to repeat itself with several viral pathogens, 
including most recently, infectious myonecrosis virus (IMNV).   
Infectious Myonecrosis Virus 
  In 2002, an outbreak of a novel, severe, and unknown disease causing significant 
mortality and “white muscle” was reported in the northeastern parts of Brazil.  This 
disease was eventually named infectious myonecrosis (IMN) and it caused millions of 
dollars in losses in Brazil in 2003.26   Through some unknown mechanism, IMN spread 
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across the globe to Southeast Asia, to the island of Java, resulting in significant financial 
losses within Indonesia in 2006.44 Tremendous losses continue in both of these countries 
at very high levels, as interventions that worked to exclude WSSV, a large enveloped 
DNA virus, and the vectors of WSSV, appear to be ineffective at preventing and 
excluding IMN from shrimp farms.   
IMNV disease and pathology 
The causative agent for IMN was eventually isolated and named infectious 
myonecrosis virus (IMNV).  IMNV is a non-enveloped, small (40 nm), icosahedral, non-
segmented, dsRNA virus, and is a member of the family Totiviridae.37 IMN disease was 
subsequently reproduced in SPF animals by injection of sucrose density gradient purified 
IMNV virions, thus fulfilling Rivers’ postulates.38 Mortality attributed to IMNV can 
range from 40% to 70% over a growout period, with large losses in production that can 
continue even following a reduction in stocking density.  Feed conversion ratio (FCR) 
can vary from a normal 1.5 to upwards of 4.41, causing increases in feed input costs.  
IMN disease itself is characterized by skeletal muscle necrosis, often grossly described as 
“white muscle,” in the distal abdominal segments followed by mortality, especially 
following periods of acute stress such as during cast netting or harvesting. 
Histopathologically, animals demonstrate a characteristic coagulative necrosis of skeletal 
muscle with fluid accumulation in between muscle fibers, along with pronounced 
hypertrophy of the lymphoid organ due to accumulation of spheroids.37 Specific 
diagnostic tests for IMNV have been developed that include the use of in situ 
hybridization on histopathology slides37 and a quantitative Real-Time RT-PCR from 
tissues.1 Outbreaks in Brazilian farms have been observed in association with the dry 
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season.  An epidemiological survey conducted in Brazil among four farms in an endemic 
area over the course of a year, found long rearing periods and high stocking densities as 
two factors highly associated with significant increases in IMN occurrence.2 
IMNV genome and related viruses  
Several Totiviruses have recently been discovered in other species including, 
Armigeres subalbatus, a mosquito vector for the parasite Wuchereria bancrofti. This 
virus shares some sequence homology with IMNV with a 29% amino acid identity within 
the capsid protein and a 44% amino acid identity with the viral RNA dependent RNA 
polymerase.63 In addition, deep sequencing of Drosophila cell lines revealed 5 additional 
previously unknown viruses, including a Totivirus with sequence similarity to IMNV, 
named Drosophila totivirus (DTV).60 Recently, Leishmania RNA virus 1 (LRV1), a 
totivirus of the Trypanosomatid protozoan parasite Leishmania, has also been shown to 
be associated with an increase in the pathogenicity and severity of Leishmania parasitic 
infections in vivo18, indicating that a Totivirus infection within a parasite may modulate 
host pathogenesis in some manner.  
IMNV and other members of the family Totiviridae contain two open reading 
frames (ORFs) in a single genome segment.  For IMNV, ORF1 (nucleotides 136-4953) 
encodes a 1606 amino acid major capsid protein (MCP) and ORF2 (nucleotides 5241-
7451) encodes a 736 amino acid RNA dependent RNA polymerase (RdRp)37. The IMNV 
ORF1 sequence encodes a 1605 amino acid polypeptide including the N-terminal 
sequence of the major capsid protein.  The IMNV capsid is isometric with a diameter of 
approximately 400 angstroms.  In addition to these two ORFs, recent studies of the 
IMNV genome have discovered a “2A-like” cleavage and “shifty heptamer” that may 
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contribute to formation of a capsid protein-RdRp fusion protein and three putative 
cleavage protein products of ORF 1.35 These putative protein cleavage products have 
been described as Protein 1, Protein 2, and Protein 3 by Nibert (2007).  There remains 
some speculation as to the precise role of these proteins.  Protein 1 is a 60 amino acid 
protein at the N-terminal region of ORF 1, and shares sequence similarities with known 
dsRNA binding proteins, thus it may be involved in host immune suppression.48 This is a 
host evasion strategy seen in RNA viruses in other arthropods.  For example, Drosophila 
C Virus (DCV) and Flock House Virus (FHV) are pathogenic single stranded RNA 
viruses of other invertebrate species that encode proteins that have dsRNA binding 
activity with the capacity to modify or inhibit the host RNAi machinery 23,53 and thus 
suppress the antiviral immune response of the host.  Protein 1 may be fulfilling a similar 
immunomodulatory role for IMNV as to the dsRNA binding proteins characterized in 
these other invertebrate viruses.   
 Protein 2 a 32 kDa protein spanning bases 415-1266 and Protein 3 a 38 kDa 
protein spanning 1267-2247, together representing the first 704 amino acids of ORF1, 
have been speculated to be candidate minor proteins visualized on viral protein 
denaturing gels, however this remains speculative in nature.48 Protrusions of fiber-like 
densities on the fivefold axis of symmetry were observed in transmission electron 
microscopic images and further investigated by cryoTEM using 3D reconstruction.48 
These protrusion proteins may be involved in the pathogenesis and transmission of 
IMNV, which is a fairly uncharacteristic member of the Totiviridae, as many members of 
this family are associated with latent or avirulent infections in the host.  Close inspection 
of these fiber complexes estimated them to be approximately 90 kDa, leading some 
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authors to speculate that a Protein 2 and Protein 3 heterotrimer may be likely candidates 
for forming these 5f fiber complexes, but the exact protein structure of these fibers and 
their role in pathogenesis remain elusive.48   
 Analysis of all the sequence data available identifies a replication strategy similar 
to one of closest relatives to IMNV, Giardia lamblia virus (GLV).   In addition to a 
similar replication strategy, these viruses appear to possess cleavage elements similar to 
invertebrate infecting members of the segmented dsRNA Reoviridae.  Experiments 
conducted using Giardia lamblia virus, demonstrated that a specific cell receptor is 
utilized for virus entry into cells, and that protection was conferred to mutants lacking 
this receptor.45 These experiments suggest that a specific cell membrane receptor likely 
exists within shrimp cells, and a ligand present on the 5- fold fiber complexes of IMNV 
could provide an avenue for entry into shrimp these cells.  Recent work using yeast two-
hybrid screens identified shrimp laminin receptor (LamR) as interacting with capsid 
proteins of IMNV, as well as other shrimp RNA viruses, providing some evidence that 
this may be a putative cellular receptor for IMNV.5 Using this data, which underscores 
the importance of these regions and cleavage products of ORF1, a series of sequence 
candidates from this region were chosen as RNAi targets in studies described within this 
dissertation.    
Shrimp Vaccination  
With the severe impact viral disease has on shrimp farming, there has been a keen 
interest in developing antiviral prophylaxis or therapies to mitigate disease.  Strategies for 
developing these for shrimp viral diseases have taken many forms.  The first has 
exploited viral envelope proteins in order to interfere with virus/host cell and cell 
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receptor interactions.   This mechanism was hypothesized to be responsible for protection 
from WSSV observed following the oral administration of formalin inactivated virus.34 
This has since been followed by several other strategies using recombinant protein 
administration, mammalian derived antisera, DNA vaccination, or delivery via bacterial 
expression systems.    
Protein subunit vaccines to WSSV envelope proteins have been shown to confer 
protection against WSSV infection in several species of marine shrimp and freshwater 
crayfish. WSSV contains at least 4 major envelope proteins with no known homology to 
other virus proteins; these are VP28, VP26, VP24, and VP19.  VP28 is present on the 
outer membrane and is likely involved in cellular entry.32 VP28 antisera raised in rabbits 
has been shown to neutralize virus in vivo.32 Recent studies have demonstrated that these 
four major envelope proteins bind to form a complex, via several pairwise protein 
interactions and one self-association (via VP28).66   This provides some evidence that 
these proteins interact and are likely involved in viral entry into target cells, making them 
ideal targets as subunit vaccine candidates or for antiviral prophylaxis.   
Subunit protein vaccines consisting of both VP28 and VP19 recombinant proteins 
conferred protection to WSSV infection and protection was seen up to 25 days post 
administration.59 More recent approaches have tested co-inoculating shrimp with 
recombinant cellular receptor proteins and virus, such as using Laminin receptor (Lamr), 
the protein proposed to be the cellular receptor for Yellowhead virus (YHV) and Taura 
syndrome virus (TSV), two other highly pathogenic RNA viruses in shrimp.5 
Experiments demonstrated that recombinant laminin receptor (rLamr) produced in yeast 
protected shrimp from laboratory challenge with YHV when virus and recombinant 
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protein were co-inoculated.5 This observation is thought to due to a “blocking” effect 
mediated by interference caused by rLamr between viral attachment and cellular entry.        
DNA vaccines encoding various WSSV envelope proteins have also demonstrated 
some efficacy in preventing or reducing infection.  Naked DNA vaccines for VP28 and 
VP281 were injected into Penaeus monodon, and demonstrable protection was observed 
for up to 7 weeks following injection.42 However, injection of naked DNA or plasmid 
DNA into individual animals is not ideal in a commercial setting due to cost of DNA 
production and feasibility of individual animal injections in the field.  Additionally, dose 
requirements to induce protection may be prohibitively expensive.   
Other groups have tried recombinant protein expression via bacterial organisms.  
Ning et al. demonstrated that Salmonella typhimurium expressing VP28 conferred 
protection in crayfish against WSSV infection for up to 25 days following oral 
administration and that the bacteria could be isolated from the animals up to seven days 
post treatment.36 However, several problems with using attenuated or genetically 
modified bacterial expression systems exist.  Current methods still require the 
introduction of live organisms that may have the ability to revert to virulence and may be 
pathogenic to humans.  Additionally, there is a large amount of consumer anxiety over 
the use of genetically modified organisms and genetically modified bacteria and DNA.   
Many strategies to select for genetic modification involve the use of antibiotic resistance 
markers, a growing concern in food borne illness pathogens.  This combination of 
regulatory, safety, and cost hurdles impedes a viable strategy for introducing recombinant 
protein or protein subunits expressed via bacterial organisms as a prophylaxis into 
commercial shrimp farms.   
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RNAi 
Exploiting the RNA interference or RNAi pathway has been developed as a novel 
strategy to mitigate viral disease that requires no protein or protein expression.46   Instead 
of administration of a recombinant subunit protein or DNA vaccines expressing a protein, 
modulation of RNA transcription has been highly successful in preventing mortality 
caused by a variety of pathogenic shrimp viruses. The RNAi pathway was first 
characterized in the model nematode C. elegans by Fire et al.12, who was subsequently 
awarded a Nobel Prize for this significant discovery. RNAi or RNA interference is a term 
describing a sub-cellular process that results in messenger RNA degradation and 
subsequent suppression of gene expression in a gene-specific and highly sequence-
dependent manner.  It is likely that RNAi evolved naturally as an antiviral mechanism in 
plants and invertebrate species.  To modulate gene expression, RNAi triggers, including 
small interfering RNAs (siRNA) and double stranded RNAs (dsRNA), can be provided 
exogenously to shrimp to induce this pathway. RNAi has become an invaluable tool for 
studying invertebrate physiology and host-pathogen interactions.  For example, RNAi has 
been observed as an antiviral response in mosquitoes that transmit human viral 
pathogens.19   This has been proposed as a possible strategy to inhibit viral transmission 
in transgenic mosquitoes expressing an RNAi trigger in the form of an inverted-repeat of 
the Dengue virus (DENV) genome.14 This tool would provide special utility in species 
such as penaeid shrimp, which lack an in vitro model or cell culture system for study. 
There is evidence that the requisite RNAi machinery is present and functioning in 
penaeid shrimp in a similar manner to other model invertebrates.8,47,51 Exploiting this 
RNAi machinery using dsRNA has been demonstrated to prevent infection or mortality 
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caused by several different shrimp viral diseases, in both a sequence dependent and 
independent manner.21,31,39,50,57 Based on these studies, RNAi is a promising approach to 
shrimp disease control.16,20,39,40,46 Specific RNAi triggers have been demonstrated to 
prevent diseases caused by WSSV39,61, Yellow head virus (YHV)49,50,62, Taura Syndrome 
Virus (TSV)41 Penaeus stylirostris densovirus (PstDNV) (formerly called infectious 
hypodermal and hematopoietic necrosis virus (IHHNV))17, and IMNV30.  Other research 
examining the ability of dsRNA to not only prevent, but treat both natural and simulated 
viral exposures has also been reported.3,17,50,61 
In addition to a being a useful mechanism to exploit for treatment and prevention 
of viral disease, RNAi has proven extremely useful in elucidating the functions of shrimp 
gene function.    Previous studies have demonstrated a global effect throughout shrimp 
tissues following inoculation, however, the mechanism facilitating this spread and 
distribution remains unknown.21 In C. elegans, it occurs via a transmembrane protein 
called SID-1, a mediator for dsRNA uptake11 and necessary requirement for global 
signaling.58   Recently, the roles of SID-1, Argonaute-1 (Ago-1), and Argonaute-2 (Ago-
2) homologues in uptake and processing of dsRNA within shrimp cells have begun to be 
studied.22 Ago-1 and Ago-2 are thought to be a critical catalytic component of the RNA 
induced silencing complex (RISC), the protein that facilitates degradation of target RNA.  
These genes have been characterized as core components of the RNAi system in some 
shrimp species, and are thought to be critical in the RNA binding activity of RISC.22 
Additionally, L. vannamei Sid-1 (Lv SID-1) was shown to be significantly upregulated 
along with members of the Argonaute gene family, specifically Ago-2, when shrimp were 
administered dsRNA of various sequences.22   This effect was only observed when 
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duplexes are greater than 50bp in length were administered, and not with siRNAs (20-
30bp), likely indicating a necessary length requirement for efficient RNA transport into 
the cell or assembly into the RISC complex.    Double-stranded RNA specific to Lv Sid-1 
reportedly causes significant mortality, indicating that it likely has other necessary 
functions in addition to RNAi facilitation.22 
Nanoparticle delivery of RNAi 
Specific RNAi signaling induces strong antiviral responses, however no feasible 
delivery vehicle has been developed to exploit this mechanism at a population scale such 
as in a pond culture system.  One preliminary delivery system that showed some efficacy 
used nanoparticles made of chitosan, a natural product made from deacytlation of chitin 
extracted from shrimp exoskeleton or shells.  These nanoparticles were manufactured 
using chitosan that had been mixed with VP28 dsRNA, a sequence corresponding to 
coding regions of subunit envelope glycoproteins of WSSV.43 Nanoparticles were then 
top-coated onto feed along with an ovalbumin binder and fed to juvenile P. monodon.  
This preparation conferred 37% increased survival over controls following administration 
and subsequent challenge with WSSV.  This same study also described protection 
conferred administering feed coated with inactivated DE3 E. coli that had been induced 
to express VP28 dsRNA.  Animals administered this feed demonstrated 67% survival 
over controls following challenge with WSSV, the best protection observed in the 
experiment.  
   Chitosan nanoparticles have also shown preliminary efficacy in other arthropod 
species such as mosquitoes.65 In a recent study, the authors demonstrate that chitosan 
nanoparticles can be used to silence endogenous genes in mosquito larvae, including 
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chitin synthase genes in Anopheles gambiae (the African malaria mosquito).  Results 
from this work provide a proof of concept for an oral delivery route for RNAi that could 
be used to silence both viral and endogenous genes in multiple arthropod species.  This 
paves the way for an entire new generation of RNAi based antiviral therapies for 
commercially important arthropods such as shrimp.  In addition, due to the versatility of 
RNAi, it could provide the foundation for novel and highly targetable pesticides targeting 
agricultural pests or disease vectors.  To further these goals, additional research into 
dosage, production of commercial scale quantities of dsRNA, and refinement of 
administration and delivery protocols needs to be conducted.   
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Abstract 
The necrotizing hepatopancreatitis bacterium (NHPB) is difficult to preserve and 
has not been propagated in vitro.  NHPB can be maintained continuously by simply 
adding specific pathogen free (SPF) shrimp to tanks containing NHP infected shrimp.  
However, obtaining large amounts of highly concentrated infectious material free of 
contaminating bacterial flora for repeating challenge experiments was found to be 
exceedingly difficult using the current published methods.  Therefore, a system was 
implemented using visible implant elastomer (VIE) tags to identify animals within a 
propagation tank by introduction group. Utilizing this method allowed for continuous 
reproduction of NHP within propagation tanks and provided researchers with access to 
infectious material allowing for consistent replication of challenge experiments and 
concentrated material for preservation.   
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Introduction 
The necrotizing hepatopancreatitis bacterium (NHPB) is a gram-negative, 
pleomorphic, obligate intracellular bacterium.3  Phylogenetic analysis of 16S rRNA has 
placed it in the α-subclass of Proteobacteria, along with such pathogens as Rickettsia 
(~83.5% similarity).5 Clinical signs of infection include a reduction in feed intake and 
empty guts, softened shells, flaccid muscle tissue, epicommensal fouling, darkened gills 
and pleopods, and atrophy of the hepatopancreas organ.4  NHPB causes a disease in 
shrimp characterized by a 2-6 week incubation period followed by high mortality that 
peaks at 34 days post exposure.8  
In vitro propagation has not been successful, however, NHPB can be maintained 
continuously by adding SPF shrimp to tanks containing NHP affected shrimp.7 However, 
consistently reproducing viable infections from propagation tanks maintained as per 
Vincent was found to be exceedingly difficult and highly variable.   Our observations 
replicating this method corresponded with previously published data, where only 25% of 
challenged individuals became infected.  Therefore, the purpose of these studies was to 
establish a target period post infection where individuals with high amounts of infectious 
material could be identified and used for consistent replication of challenge experiments 
or preservation.   
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Materials and Methods 
Post larval specific pathogen free (SPF) pacific white shrimp were obtained from 
the Oceanic Institute, Kailua-Kona, Hawaii.     Animals were maintained at 27 + 2ºC, 
salinity 30 + 2 parts per thousand (ppt) in synthetic seawater with constant airstone 
aeration.  Each tank was equipped with a carbon filter and an oystershell airlift biofilter.  
Shrimp were fed a maintenance diet twice daily (Shrimp Production Formula 45/10, 
Rangen Inc., Buhl, Idaho).  Water quality was monitored weekly by measuring ammonia 
and nitrite levels (Nitriver 3, Hach Company, Loveland, CO).   
Origination and maintenance of NHPB infected shrimp 
   NHPB infected shrimp were obtained from Amanda Vincent, Gulf Coast 
Research Laboratory, University of Southern Mississippi, Ocean Springs, MS.  Infected 
shrimp were maintained in 160 gallon tanks containing approximately 80 gallons of 
artificial salt water, temperature 30 + 2ºC, salinity 30 + 2 ppt.  Each tank was equipped 
with a carbon filter, oystershell biofilter, supplemental tank heater, and constant aeration. 
As animals in the infected tanks died, carcasses and moribund animals were left in the 
tanks and SPF shrimp were added to replace them as reported by Vincent et al 8 to 
facilitate transmission by per os exposure to infectious animal remains. 
In vivo propagation of NHPB infected shrimp 
Initially, 3 propagation tanks (E, F, and G) containing 25 animals were challenged 
per os with infected hepatopancreas tissue.   Each time a new introduction group of SPF 
animals were added to a tank, each shrimp was injected with a visible implant elastomer 
(VIE) tag (Northwest Marine Technology, Shaw Island, Washington) in the dorsal 
skeletal muscle of the last abdominal segment. The day each group was added to the tank 
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was recorded along with the corresponding tag color.  The number of shrimp in each tank 
was maintained at approximately 25 (+/- 5) shrimp.  A total inventory of each tank was 
conducted daily and the color of shrimp which were dead, moribund, or missing was 
recorded.  When dead or moribund shrimp were found with an intact HP, approximately 
0.1 g of tissue was collected in a 1.7 mL microcentrifuge tube and stored at -20 ºC for 
testing by PCR analysis.  These data were used as a basis for selection of shrimp likely 
infected with high levels of NHPB for challenge experiments.  Kaplan-Meier survival 
curves were generated with survival time calculated from the date of introduction until 
date of death by NHP (FIGURE 1). After 120 days of the experiment a negative control 
tank was initiated in a room separate and in isolation from the room containing the tanks 
with NHPB infected shrimp (FIGURE 2).  The parameters for maintenance of the 
negative control tank were identical to those for the tanks containing NHPB.  At this 
time, the inventory level of each tank was increased to 40 shrimp per tank (TABLE 1).    
PCR extraction procedure 
Total genomic DNA was extracted from each HP sample according to the 
instructions found in the High Pure PCR Template Preparation Kit (Roche Applied 
Science, Indianapolis, Indiana).  Template DNA was maintained at 4ºC to be run in a 
PCR within 48 hours and stored at -20ºC for long-term use. 
PCR protocol 
NHP primer sequences, positive control DNA, and PCR protocol were obtained 
from Dr. Donald Lightner, University of Arizona, Tucson, AZ.  NHP PCR was conducted 
using puReTaq Ready-To-Go PCR Beads (GE Life Sciences, Piscataway, NJ, USA).  
Primers sequences used were NHPF2: 5’- CGT TGG AGG TTC GTC CTT CAG T-3’ 
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and NHPR2: 5’- GCC ATG AGG ACC TGA CAT CAT C-3’.  PCR reactions were 
performed in a GeneAmp PCR System 9700 (PE Applied Biosystems, Carlsbad, CA, 
USA) with the following cycling conditions: Step 1: 95ºC for 2 minutes, 1 cycle; Step 2: 
95ºC for 30 seconds, 60ºC for 30 seconds, 72ºC for 30 seconds, 25 cycles; Step 3: 60ºC 
for 1 min, 72ºC for 2 minutes, 1 cycle; 4ºC infinite hold.  PCR products were run on a 
pre-cast 2% Invitrogen E-gel (Invitrogen, Carlsbad, California) in order to confirm 
product size via comparison to a pGEM DNA ladder (Promega, Madison, WI).  DNA 
was visualized using Gel Doc imaging software (Bio-Rad Laboratories, Hercules, CA). 
Histopathology 
In order to confirm the presence of NHPB within the tank system, fecal PCR 
positive animals were fixed whole in Davidson’s fixative for 24 hours and then stored in 
70% ethanol before being examined by histopathology.  Presence of NHPB within the 
system was confirmed by immunohistochemistry at the Iowa State Veterinary Diagnostic 
Lab, Ames, IA utilizing techniques described by.6 
Results 
The propagation tanks were established and continually maintained for over 7 
months in which SPF shrimp were naturally exposed to shrimp infected with NHPB.  
Over 1000 individuals in over 120 introduction groups were tracked through the tanks.  
The mortality rate of shrimp remaining in the propagation tanks was 100% with a 
maximum time until death of 134 days (FIGURE 1).  Antemortem study samples as well 
as postmortem and moribund tissues were consistently positive for the presence of NHPB 
as determined by PCR analysis of hepatopancreas tissue.  In addition, clinical signs, gross 
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and histopathologic lesions consistent with NHP were observed in shrimp examined from 
the propagation tanks.  Negative control SPF shrimp held in an isolation room separate 
from the NHPB propagation tanks had a mortality rate of 30 % with a range until death of 
1 day until termination at 173 days.  Shrimp removed periodically from the negative 
control tank were all negative for NHPB by PCR analysis.  No evidence of NHP was 
observed by clinical signs, gross lesions or histopathologic examination of shrimp from 
the negative control tank.   
NHPB was consistently detected in the hepatopancreas tissue from infected tanks 
by PCR (TABLE 2).  In addition, tissues which were removed from infected shrimp for 
various experiments not reported here1 were consistently found to be positive for NHPB 
by PCR and by histopathologic examination.  Hepatopancreas tissues collected from 
shrimp found dead or removed alive from the negative control tank were consistently 
found negative for NHPB by PCR (TABLE 2).   Shrimp removed from the control tank 
on day 313 and which had been in the tank for 165 days were PCR negative for NHPB 
and were found to not contain lesions of NHP by histopathologic examination.   
Discussion 
The purpose of this study was to establish an in vivo propagation system for the 
production of concentrated infectious material.  This was done by tracking individual 
animals using an elastomer tag, coded to an introduction group, thus allowing the 
duration of the exposure period to quickly be assessed.  It involved a per os natural 
exposure providing a closer model of pond conditions within the laboratory.  This 
 37 
infectious material was used consistently for a wide array of studies including 
development of preservation techniques 2 and challenge models.  
During the study period over 1000 individual shrimp in over 40 introduction 
groups were followed through the tanks and were used to consistently reproduce 
infections in other experiments by selecting infected individuals in the acute stages of 
infection that were positive by PCR analysis.2 Previous long-term maintenance models 
developed by Vincent et al. utilized addition of SPF shrimp to maintenance tanks every 
21-28 days containing populations of approximately 50 individuals. Due to difficulties in 
reproducing experimental infections in this method, the described modifications were 
made.   In order to increase the likelihood that tissue removed contained high levels of 
NHPB, individual shrimp were followed throughout the exposure period.  The 
implementation of this method appears to remedy some of the difficulty described by 
Vincent in obtaining large amounts of infectious material for replicating challenge 
experiments, where only a quarter of individuals exposed were diagnosed as positive for 
NHPB following exposure.7 In order to effectively select individuals during the acute 
stages of infection, and thus the highest concentration of bacteria within the challenge 
tissue, animals were sacrificed immediately prior to the period with the highest mortality 
rate.   This period was found to begin at approximately day 18 after introduction and end 
at approximately day 25 (FIGURE 1 and 2).  Outside of this period reproduction of 
disease in challenge experiments was found to be quite variable.  Vincent and Lotz 
reported a peak in mortality of 34 days which was similar our results of 27 and 34. 8 The 
time course observed differed somewhat from studies done by Vincent et al 8 when 
characterizing time course of disease.  A longer duration of the chronic disease state was 
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observed as many PCR positive individuals never succumbed to the disease until well 
after 100 days of exposure; however this was not confirmed by histopathology.  In 
conclusion, these methods allow for repeatable reproduction of NHP disease within L. 
vannamei from ongoing propagation tanks and enable researchers to have access to a 
consistent supply of infectious material for challenge models and experiments.  This 
provides for consistent access to inoculum from specific animals with known exposure 
periods, thus reducing the number of low titer animals in the challenge pool.      
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TABLE 1. Number of individual animals added and removed prior to death 
      
Prior to 
Control        
With 
Control     
                    
Tank   E F G   E F G Control 
                    
Total No. 
Added 100 141 139   221 203 226 81 
                    
No. Removed 
for experiment 20 30 19   30 33a 38 34a 
                    
No. Plotted in 
Figure 1 and 2 80 111 120   191 170 188 47 
 
a includes shrimp that died due to loss of aeration 
 
 
 
 
 
 
 
 
 
TABLE 2. PCR surveillance testing results from NHP propagation tanks following 
initiation of control tank 
 
Tank # NHP Positive # NHP Negative Total Tested % NHP Positive 
G 66 0 66 100.0 
F 73 1 74 98.6 
E 61 1 62 98.4 
Control 0 7 7 0.0 
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FIGURE 1. Kaplan–Meier survival curve generated with survival time calculated from 
the date of introduction into propagation tank until date of death by necrotizing 
hepatopancreatitis (NHP). Shrimp that were removed or died of causes other than NHP 
were censored at the time time of loss. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 43 
 
 
 
FIGURE 2.  Kaplan–Meier survival curve generated with survival time calculated from 
the date of introduction into propagation tank until date of death by necrotizing 
hepatopancreatitis (NHP) following addition of the control tank.  Shrimp removed for 
experimental studies or that died of causes other than NHP were censored at the time of 
loss. 
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Abstract 
Viral diseases are significant impediments to the growth and sustainability of 
commercial shrimp aquaculture.  New viral diseases continue to emerge and, along with 
endemic disease, cause significant economic losses to shrimp production.  Disease caused 
by Infectious myonecrosis virus (IMNV) has caused tremendous losses in farmed Pacific 
white shrimp (Litopenaeus vannamei), the predominant species used in shrimp 
aquaculture, since IMNV emerged in Brazil and subsequently spread to Indonesia.  There 
are no existing antiviral treatments or interventions, outside of pathogen exclusion, to 
mitigate disease in commercial shrimp operations. Novel RNA interference (RNAi) 
strategies that employ exogenous double-stranded RNA (dsRNA) are a promising means 
to approach disease control.  Here we describe an iterative process of panning the viral 
genome of IMNV to discover RNAi trigger sequences that initiate a robust and long-
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lasting protective response against viral disease in L. vannamei.  Using this process, a 
single, low dose (0.02 µg) of an 81 bp and 153 bp fragment targeting the 5’ end of the 
viral genome was discovered which protected 100% of animals from disease and 
mortality caused by IMNV.  Furthermore, animals that were treated with highly 
efficacious dsRNA survived an initial infection and were resistant to subsequent 
infections 50 days later with a hundred-fold greater dose of virus.  This protection is 
highly sequence dependent, because dsRNAs specific to IMNV, but targeting the coding 
regions for the polymerase and structural protein regions of the genome, conferred lesser 
or no protection to animals.  Interestingly, non-sequence specific or heterologous dsRNA 
did not provide any degree of protection to animals as had been described for other 
shrimp viruses.   Our data indicate that the targeted region for dsRNA is a crucial factor 
in maximizing the degree of protection and lowering the dose required to induce a 
protective effect against IMNV infection in shrimp.     
Introduction  
Viral diseases that impact cultured shellfish are considerable impediments to 
successful, sustainable aquaculture practices and trade, and have the most profound 
economic impact in developing, tropical countries that provide optimal climate and 
habitat for shrimp aquaculture.   The Pacific white shrimp, Litopenaeus vannamei 
(Decapoda: Penaeidae), is uniquely amenable to aquaculture and has rapidly become the 
dominant farmed shrimp species globally; indeed, production of L. vannamei increased 
from 8,000 metric tons in 1980 to 1.38 million tons in 2004 worldwide.6 Pathogen 
translocation and disease outbreaks have ensued with increasing production, and 
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significant economic losses have resulted with the emergence of each of the major viral 
pathogens.29 Epizootics of viral diseases in particular cause substantial mortality in L. 
vannamei and result in devastating financial losses; it has been estimated that annual 
losses globally as a result of diseases (mostly viral in etiology) have been as high as 3 
billion USD.13,30 The occurrence of a pathogenic virus in a pond of growing shrimp 
exerts a range of consequences, including forcing the grower to prematurely harvest, 
increasing production costs through decreased feed conversion, or causing a complete 
loss of animals.29 Beyond deliberate pathogen exclusion or selective breeding, which is 
not effective against all viral pathogens, there are no means to control or treat viral 
disease and prevent perpetual transmission in farmed shrimp.  A practical and efficacious 
means of protecting shrimp against viral disease would offset these losses and facilitate 
more profitable production of farmed shrimp in this multibillion dollar per year industry. 
RNA interference (RNAi) is promising and emerging approach to shrimp disease 
control.9,10,17,18,21 RNAi is a sub-cellular process that results in gene-specific RNA 
degradation.  RNAi triggers, including small interfering RNAs (siRNA) and double 
stranded RNAs (dsRNA), can be provided exogenously to arthropod cells or whole 
organisms to study gene function.  In recent years, RNAi has become an invaluable tool 
for studying arthropod physiology and arthropod-pathogen interactions.  It is likely that 
RNAi evolved, in part, as an antiviral response.  Indeed, the RNAi phenomenon also has 
been observed as an antiviral response in mosquitoes that transmit human viral pathogens 
and has been proposed as a transmission-blocking strategy in which transgenic 
mosquitoes, expressing an RNAi trigger in the form of an inverted-repeat of the Dengue 
virus (DENV) genome, no longer support amplification and transmission of the virus.7 
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There is evidence that the requisite RNAi machinery is present and functioning in a 
similar manner in penaeid shrimp.4,22,27 Therefore, RNAi is an attractive means to 
specifically disable virus infection in shrimp cells and thereby protect shrimp from 
associated pathology and morbidity.  Indeed, specific RNAi triggers mitigate disease 
caused by White Spot Syndrome Virus (WSSV)17,32, Yellowhead Virus (YHV)25,26,33 and 
Taura Syndrome Virus (TSV).19 
Infectious Myonecrosis Virus (IMNV) is a non-enveloped, double stranded RNA 
(dsRNA) virus that is a member of the Totiviridae family.  IMNV was first discovered in 
2003 after a severe disease outbreak in 2002 in Brazil that was characterized by high 
mortality and animals exhibiting necrosis in the tail muscle.16 In previous outbreaks, 
mortality has ranged from 40% to 70% prior to harvest.1 Moribund animals have ever-
increasing opaque to white muscle tissue visible through the cuticle, starting in the 
ventral portion of the muscle and expanding dorsally in each abdominal segment. 
Histopathologically, animals demonstrate a characteristic coagulative necrosis of skeletal 
muscle with fluid accumulation between muscle fibers and pronounced hypertrophy of 
the lymphoid organ due to formation of spheroids, well-delineated non-tubular 
aggregates of lightly basophilic cells, a feature common to several virus infections that 
affect shrimp.16 
IMNV reached Indonesia in 200620; this translocation of the pathogen is evidence 
for a very real risk for spread throughout Asia and the world.  Due to the current and 
tremendous future potential impact this disease has on the shrimp industry, development 
of a vaccine or mitigation strategy is prudent. The aim of this work was to discover and 
optimize RNAi trigger sequences that would elucidate a protective response to IMNV.  
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We describe an iterative process of panning the IMNV genome for antiviral sequences 
through which we arrived upon a targeted RNAi trigger for a short, precise portion of the 
5’ end of the IMNV genome that confers long-lasting and robust protection against 
IMNV when administered in a single, low dose. 
Materials and Methods 
Animal Rearing 
Specific pathogen free (SPF) postlarvae were received from Shrimp Improvement 
Systems (Plantation Key, Florida) and reared in a biosecure animal holding facility at 
Iowa State University.   Animals were placed into 1000L Poly tanks containing artificial 
seawater (Crystal Sea Marine Mix), an oystershell airlift biofilter, and an activated carbon 
filter.  Animals were fed a commercial growout diet until ~5 grams in weight.    
Preparation of Virus Inoculum 
Based on a previously described methodology8, tissue macerate from infected 
animals was diluted 1:3 in sterile TN buffer (0.02 M Tris-HC1, 0.4 M NaC1, pH 7.4) and 
clarified through three centrifugation steps after which supernatant was removed by 
subsequent centrifugation: 1) 4000 x g for 30 minutes, 2)  15,000 x g for 15 minutes 3)  
25,000 x g for 60 minutes.   The final supernatant was diluted 1:10 in 2% saline and 
passed through a 0.2 micron filter.   This stock viral clarification was aliquoted and 
frozen at -80C and aliquots of this stock were thawed for each viral challenge.  
Quantitative polymerase chain reaction (qPCR) analysis of RNA extracted following a 
freeze-thaw cycle indicated 105 viral copy numbers/µL were present in the stock.   
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Determination of Challenge Dose 
The optimum dose by injection resulting in infection and disease was tested in 20 
SPF animals weighing 8-10 grams. Each animal was injected with 100 µL of stock, 1:10 
or 1:100 dilutions thereof, or 2% NaCl (sham) into the third abdominal segment.  
Animals were observed twice daily for mortality.  All virus inoculums resulted in 100% 
mortality at varying time points.  Using these infectious doses, optimum survivorship was 
observed with the 1:100 dilution, after which 100% of shrimp died by 18 days post 
infection (dpi) as compared to the stock dilution that resulted in 100% mortality between 
1 and 2 dpi, the 1:10 dilution which resulted in 100% mortality at 11 days, or the 1:100 
dilution which resulted in 100% mortality at 18 days. The 100-fold dilution of the stock 
virus was used as the viral challenge dose for the described challenge experiments. 
Challenged shrimp show characteristic opaque tissue and hypoxic body posturing 
(FIGURE 1).     
Quantitative Reverse-Transcription PCR 
Quantitative Reverse-Transcription PCR (qRT-PCR) was performed by using 
methods adapted from Andrade et al.1  RNA template was purified using an RNeasy 
Minikit (Qiagen).  Briefly, 30 mg of muscle tissue was dissected from the tail and placed 
in 600 µL of Buffer RLT.  This was then transferred to and mascerated in a ground glass 
tissue grinder for approximately 100 turns.  The tissue mascerate was then homogenized 
on a QIAShredder column (Qiagen) and purified using RNeasy centrifuge columns 
according to manufacturer’s instructions.  50 µL of RNA template was eluted into RNase 
free water and stored at -80 °C until the RT-PCR was performed.  For the qRT-PCR 
templates were thawed and boiled at 100 °C for 5 minutes prior to reverse transcription. 
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One-Step RT-PCR Kit (Qiagen) was used. 2 µL of RNA template was mixed with 5 µL 
of 5x One Step RT-PCR Master Mix (Qiagen), 1 µL Enzyme Mix, 1 µL DNTP, 0.3 µL 
IMNV412 (20 uM) (5′-GGA CCT ATC ATA CAT AGC GTT TGC A-3′) , 0.3 µL 
IMNV545R (20 uM) (5′-AAC CCA TAT CTA TTG TCGCTGGAT-3′), 0.3 µL IMNV 
p1 (10 uM) (5′-6FAM CCA CCT TTA CTT TCA ATA CTA CAT CAT CCC CGG 
TAMRA-3′) and 15 uL RNase free water for a total reaction volume of 25 µL.  This 
reaction was then run in duplicate on a BioRad CFX96 Real Time PCR Detection System 
under the following conditions: RT for 30:00 at 48 °C and 10:00 at 95 °C, followed by  
PCR for 35 cycles of 15s at 95 °C and 1:00 min at 60 °C.  Viral copy number was 
calculated using CFX Manager Software (BioRad) using an in vitro transcribed RNA 
standard generated using methods similar to Andrade et al1.   
Statistical Analysis 
Statistical significance was conducted on mean log viral RNA copies/mL RNA 
and mean survival at termination of the experiment using One-way ANOVA followed by 
Tukey’s multiple comparison test using JMP 8 Software (SAS Institute Inc. Cary, NC, 
USA)  
dsRNA Preparation 
dsRNA was prepared using Ambion Megascript RNAi Kit following the  
manufacturer’s directions.  Template DNA for in vitro transcription was created by 
extracting RNA from virus infected animals using a commercial nucleic acid purification 
kit (Qiagen RNeasy Minikit).  cDNAs to IMNV genome were created using specific 
oligonucleotide primers (TABLE 1) designed from sequences available (GenBank 
accession no.EF061744)20 and reverse transcription (Thermoscript RT, Invitrogen). Five 
 51 
mL of RNA extract was added to the reaction mix and incubated at 50°C for 60 minutes 
per manufacturer’s instructions.  Following reverse transcription, template cDNA (~50 
ng) was added to a PCR master mix (PuReTaq Ready-To-Go PCR Beads, GE 
Biosciences) and thermal-cycling was performed using oligonucleotide primers (Table 1) 
designed to specific regions of the IMNV genome (GenBank accession EF061744.1).  
Products were then cloned into pCR4.0 vectors (Zero Blunt TOPO PCR cloning kit) and 
transformed into E. coli (TOP10 Invitrogen).  Plasmids preparations from these 
transformants were used as a template source for further PCRs to create DNA clones for 
RNA transcription.  Clones were sequenced and 100% identity with the IMNV genome 
was confirmed.  For synthesis of template for transcription, primers containing a T7 
promoter sequence (TABLE 1) on the forward and reverse primer were used to amplify 
the segments of cDNA with flanking T7 promoter sites.  PCR products were subjected to 
QIAquick (Qiagen) PCR cleanup to remove unincorporated nucleotides, primers, and 
enzyme.   T7 DNA templates were transcribed overnight following the manufacturer’s 
directions. Following transcription, dsRNA products were incubated for 60 minutes with 
DNase I and RNase, and purified using the provided columns.  Transcription of dsRNA 
was confirmed by gel electrophoresis in comparison with a molecular weight ladder 
(pGEM ladder, Promega) and the product was quantified by using a spectrophotometer.  
Histopathology  
Moribund animals that were found prior to death were fixed in whole Davidson’s 
fixative3 for 24 hours before being transferred to 70% ethanol, In addition, two animals 
from each tank were anesthetized in an ice slurry and fixed in Davidson’s fixative3, 
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embedded in paraffin, cut into slides, and stained with hematoxylin and eosin and 
evaluated for the presence of IMNV lesions. 
Shrimp Bioassays 
Two hundred liter tanks containing synthetic seawater and an oystershell airlift 
biofilter were stocked with 10 or 20 SPF juveniles weighing 3-7 grams and allowed to 
acclimate for 72 hours (h).  Tanks were maintained at 28 ppt salinity and 28 °C. 
Following acclimation, animals were injected intramuscularly at the desired dose and 
volume of either dsRNA corresponding to regions of the IMNV genome, a heterologous 
dsRNA control, or a sham vaccination (RNase free water diluent).  Following dsRNA 
administration, animals were challenged with IMNV intramuscularly (~3.2 x 103 IMNV 
copy numbers/µL RNA) into the third abdominal segment at the desired time point (2, 10, 
or 52 days) or a sham virus challenge (2% NaCl viral diluent) as a strict negative control.  
Animals were counted daily for mortality.  Moribund animals were fixed for 
histopathology in some experiments.  At the termination of experiments animals were 
euthanized by immersion in an ice water slurry and tissues from experiments were 
immediately frozen at -80°C.  Representative samples at termination were also fixed in 
Davidson’s fixative for histopathology.   
Target Specificity 
Tanks containing 20 SPF juveniles weighing 5-7 grams were divided into 5 virus 
challenge groups with three replicates per group.  Shrimp were injected with dsRNA 
constructs corresponding to three different segments of the IMNV genome, a 
heterologous dsRNA control (eGFP), or a sham vaccination. A total of 2.0 µg of in vitro 
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synthesized dsRNA was inoculated into animals into randomized tanks.  Animals were 
challenged with IMNV 48 hours after dsRNA administration.  
Dose Response  
Tanks containing 10 animals weighing 3-5 grams were divided into 6 
experimental groups that received a dose (2.0, 0.2 or 0.02 µg) of a dsRNA construct 
(dsRNA 95-475 or dsRNA3764-4805), Three control groups received a heterologous 
eGFP dsRNA at a single dosage of 2 µg of eGFP dsRNA. Following dsRNA 
administration, animals were challenged 2 days (data not shown) or 10 days later with 
IMNV.  
Length Dependency 
Tanks containing 10 animals weighing 3-5 grams were divided into treatment 
groups with 3 replicate tanks per treatment.  Animals were subjected to injection with one 
of six dsRNA constructs corresponding to or different truncations of the 95-475 dsRNA 
(dsRNA95-475, 193-475, 95-376, 194-275, 219-273, or 223-376).  A total of 0.02 µg of 
in vitro synthesized dsRNA was inoculated into animals that were challenged 10 days 
later with IMNV.   
Long Term Protection 
Shrimp administered 2.0 µg of dsRNA95-475 that survived virus challenge from a 
prior experiment (n=17) were subjected to a second infection at 100-fold higher dose of 
virus inoculum (~3.2 x 105 IMNV copy numbers/mL RNA), 52 days after the initial virus 
challenge and 54 days after administration of dsRNA. A naïve challenge control group 
was injected with the same challenge dosage.  Animals were followed for an additional 
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40 days after secondary challenge.  At that time the experiment was terminated and 
samples taken.   
Results 
A disease challenge model was established that uses an intramuscular injection of 
a clarified virus preparation; this protocol yields consistent morbidity, mortality and 
pathology in infected animals.  IMNV challenge resulted in 100% mortality, with 
variation in duration to mortality according to dose (FIGURE. 1).  A 100-fold dilution of 
the tissue homogenate (~3.2 x 103 IMNV copy numbers/µL RNA, data not shown) 
resulted in 100% mortality over an 18 day period and was used as the virus challenge 
dose for all subsequent experiments.  Quantitative RT-PCR (hereafter referred to as 
qPCR) provided evidence of virus replication because virus genome copy numbers 
ranged from 2.5 x 105 to 3.5 x 107 IMNV copy numbers/µL in muscle tissues sampled at 
9 day post-infection when compared with the inoculum dose (3.2 x 103 IMNV copy 
numbers/µL).  These qPCR results support histopathological observations, because 
moribund animals collected from this same experiment showed characteristic IMNV 
pathology on histopathology sections.  Negative control animals that were injected with 
sterile 2% NaCl (virus diluent) showed no signs of histopathological muscle lesions or 
trauma at the injection site and the presence of IMNV was not detected in this group by 
qPCR.   The development of this model allowed for a consistent and controlled exposure 
of virus to facilitate comparison of protection provided by various RNAi triggers. 
Three regions that encompass portions of the 5’, center and 3’ regions of the 
IMNV genome were initially chosen as targets for dsRNA design (FIGURE 2); these are 
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designated as dsRNA95-475, 3764-4805, and 5518-6391 according to the range of 
nucleotides represented from the genome (GenBank accession EF061744).  Double 
stranded RNAs were injected into shrimp in a 2.0 µg dose; animals were infected with 
IMNV, using the established challenge model, 2 days later.  Control shrimp were 
subjected to heterologous dsRNA or sham-inoculation and subsequently challenged with 
IMNV, and showed significant mortality with 1.67% and 3.33% survival, respectively 
after 30 days.  Of the animals subjected to IMNV-specific dsRNAs, 81.67% and 61.67% 
in the dsRNA95-475 and dsRNA3764-4805 groups survived IMNV infection for the 
duration of the experiment (30 days) (FIGURE 3), respectively; this is a statistically 
significant difference (P<0.001) in survivorship as compared to controls, according to 
Oneway ANOVA followed by Tukey’s multiple comparison test.  By contrast, animals 
injected with dsRNA5518-6391 had mortality similar to the sham-inoculated controls 
with 5% survival post-challenge.  No significant difference was evident between survival 
in animals injected with dsRNA5518-6391, dsRNA eGFP, or the 2% saline control 
inoculation at day 30.  All of the non-infected controls survived for the duration of the 
experiment (FIGURE 3). Further, qPCR on muscle tissues sampled from dead individuals 
at 9-14 days post-infection demonstrated a significant reduction in genome copy number 
between animals administered dsRNA95-475 or dsRNA3764-4805 (mean 2.44 x 105 and 
2.39 x 104 IMNV copy numbers/µL RNA, respectively) when compared with animals 
administered dsRNA5518-6391, dsRNA eGFP, or sham inoculation (3.44 x 108, 2.1 x 
108, and 2.72 x 107  IMNV copy numbers/µL RNA, respectively) (FIGURE 4). 
To test the longevity of the protective effect, a group of dsRNA95-475-injected 
shrimp (n=17) from the initial target specificity assay was subjected to a second infection 
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at a 100-fold higher dose, 52 days after the initial virus challenge and 54 days after the 
administration of dsRNA. Animals were followed for an additional 40 days after 
secondary challenge (94 days from the start of the experiment) and showed 94% survival 
(16/17), as compared to 10 challenge control animals that showed 100% mortality 
(10/10) within 8 days.   
Double stranded RNAs 95-475 and 3764-4805, which provided the highest 
demonstrated levels of protection were used in a dose titration study to determine the 
minimal dose to achieve protection from IMNV challenge.  Animals were injected with 
2.0. 0.2, or 0.02 µg of dsRNA95-475 or dsRNA3764-4805, then IMNV challenged at 2 d 
or 10 d post-dsRNA inoculation. As shown in FIGURE 5, 80% of animals receiving 
dsRNA95-475 were protected from IMNV challenge even at the lowest dose (0.02 µg) 
and at 10 days post-dsRNA injection.  dsRNA3764-4805 elicited this level of protection 
but only when animals were injected with 10 times the amount of dsRNA (0.2 µg) 
(FIGURE 5).   
Moribund animals were sampled for histopathological analysis from sham-
vaccinated controls, eGFP dsRNA administered controls, and the low dose (0.02 µg) of 
dsRNA3764-4805 at both 2 and 10 d post-dsRNA administration.  Evidence of IMNV 
infection and disease included extensive necrosis of muscle fibers, distributed in small to 
large irregular foci, not limited to particular muscles but scattered throughout the tail as 
well as affecting smaller muscle bundles in the cephalothorax and in the legs. The lesions 
were consistent with histopathological changes previously described as characteristic of 
IMNV infection.16 Both acute and chronic lesions were evident, often in adjacent 
locations. Acute lesions were characterized by coagulative necrosis and fragmentation of 
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muscle bundles with edema prominent within the muscle bundle sheaths and between 
affected muscle bundles. Infiltration of hemocytes was mostly limited to small clusters 
scattered along the connective tissue septa that separated groups of muscles. Chronic 
lesions were characterized by partial or total loss of myofibers with 
condensation/contraction of the fibrous connective tissue components. The hypercellular 
appearance of these bands of fibrous tissue appeared to be due primarily to collapse of 
the muscle sheaths rather than active fibroplasia.  Hemocyte infiltrates in chronic lesions 
were minimal in contrast to a previous report.16 Lymphoid organs were evaluated if 
present in the sections examined. Spheroid formation was evident and usually prominent 
in all lymphoid organs examined, with multiple spheroids affecting most of the organ. In 
contrast to histopathological observations in IMNV-infected control animals, muscle 
lesions in the dsRNA-injected shrimp that were sacrificed at termination of the trial were 
chronic in appearance. Acute muscle necrosis was not evident in most of these animals, 
but was limited to a few very small foci in an occasional animal. In addition, two animals 
that were re-challenged with additional virus and examined by histopathology showed 
mature fibrous scar tissue but did not demonstrate necrotic lesions.   
Because dsRNA95-475 provided significant (P=.0003) in comparison with 
controls), long-term protection from IMNV-induced disease, and was highly protective 
even at a low dose, this region was further scrutinized for development of shorter 
dsRNAs as depicted in FIGURE 2.  Two dsRNAs were generated as ~100 bp truncations 
from the 5’ (193-475) or 3’ (95-376) ends of the original dsRNA95-475 dsRNA.  When 
administered 10 d prior to challenge, dsRNA95-376 conferred 100% protection, whereas 
the 5’ truncation (193-475) conferred 93.33% protection in animals 30 d post-dsRNA 
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administration. This survival was statistically significant when compared with the control 
groups (P<0.0001). Shorter dsRNAs were then designed within this truncated region to 
the 194-275, 219-273, and 223-376 regions of the IMNV genome (Fig. 2).  Of these, 
dsRNA194-275 and 223-376 injected animals showed 100% survival (P<0.0001) and 
dsRNA219-273 provided 73.33% protection (P=.0005) following IMNV challenge 
(FIGURE 6).  
Discussion   
These studies describe the first use of RNAi to protect shrimp from IMNV, a 
significant emerging shrimp pathogen; moreover, our data show that very specific, short 
dsRNAs confer robust and long-term resistance to IMNV-induced disease and mortality. 
This effect is highly dependent upon sequence selection and the virus gene that is 
targeted.   
Three target regions, spanning the length of the viral genome, were selected as 
initial targets for dsRNA generation. The first target sequence (dsRNA95-475) 
corresponds to the N-terminal region of ORF1 frame 1, which is predicted to contain two 
co-translationally cleaved products, termed Proteins 1 and 2.22 Protein 1 (93 aa) and 2 
(284 aa) are encoded by nucleotides 136-415 and 416-1266 of the IMNV genome within 
ORF 1 frame 1, respectively, and their functions remain uncharacterized14.  Protein 1 
shares 35% sequence identity with previously described dsRNA binding proteins.16 In 
addition, portions of the coding regions for the major capsid protein (MCP) 
(dsRNA3764-4805) and RNA dependent RNA polymerase (RdRp) (dsRNA5518-6391)14 
also were selected for dsRNA generation.  The major capsid protein (909 amino acids) of 
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IMNV is encoded by nucleotides 2227-4953 within ORF 1, frame 1.  The RNA 
dependent RNA polymerase (736 amino acids) is encoded by nucleotides 5241-7451 
within ORF2, frame 316.  A non-specific control dsRNA was designed to an exogenous 
sequence corresponding to enhanced green fluorescent protein (eGFP).5 
Two of the three dsRNA constructs (dsRNA95-475 and dsRNA3764-4805) 
conferred significant protection from IMNV-induced disease (FIGURE 3).  The 
dsRNA95-475 that targets the 5’-most end of the IMNV genome provided the greatest 
protection from disease in terms of dose and duration.  dsRNA3764-4805 that targets the 
sequence that corresponds to the major capsid protein, provides a significant, but 
intermediate, protective effect (61.67% survival) when dsRNA is administered 48 h prior 
to virus challenge (FIGURE 3). An intermediate level of protection also was 
demonstrated with this dsRNA in a dose titration experiment, wherein a ten-fold higher 
dose was required for protection in comparison to dsRNA95-475 (FIGURE 5). This is an 
interesting finding because dsRNA corresponding to structural proteins (VP19, VP28) of 
a large DNA virus (WSSV), are very effective in reducing mortality when administered 
before challenge.19  
Specific targeting of the non-structural RdRP protein using dsRNA5518-6391 
provided no measurable protection in comparison to the sham-injection used for positive 
control animals (FIGURE 3).  This is in contrast to previous work that demonstrated 
effective protection from infection when non-structural proteins were the targets of 
silencing in other RNA viruses such as Yellowhead virus.25,33  
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Dose Response  
In order to determine threshold protective doses of dsRNA and simultaneously 
characterize a dose/response to confirm biological activity of the RNAi response, animals 
were administered doses ranging from 0.02 - 2.0 µg.  A reduction in survival was 
apparent at the lowest levels for both sequences tested, but even at the lowest doses one 
sequence (dsRNA95-475), was more protective (80%) (FIGURE 5).  This very small 
dose (20 ng) makes it an ideal candidate antiviral molecule for delivery to shrimp for the 
purpose of preventing disease caused by IMNV.  Previous reports in which dsRNA was 
used to control disease associated with WSSV infection showed protection with much 
larger quantities of dsRNA (~ 5 µg/gram of animal or higher) injected per animal18 and 
that quantities less than 1 µg of specific WSSV dsRNA were insufficient to protect from 
mortality.7 Our studies show that protection is long-lasting for IMNV, even at these lower 
doses, because dsRNA was effective at disease prevention for at least 10 days as 
compared to 5 days for YHV when a 25 µg dose was given.17  This disparity in dose 
range may be a result of dose-response titration studies that did not extend to the lower 
limit of what we tested because those authors used 100 µg as a high dose and 7-15 µg as 
the intermediate dose19 or extrapolated a dosage based on 5.0 µg of dsRNA being 
sufficient to suppress endogenous genes17.  This work demonstrates that vastly smaller 
amounts of specific dsRNA provide sufficient robust and long-term protection, against 
IMNV disease (0.02 µg for 10 days).  This provides new insight into the capacity of the 
shrimp RNAi machinery and demonstrates the power of developing RNAi antivirals 
through target optimization in devising a more cost-effective approach to shrimp disease 
control.     
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Target Specificity 
The most significant protection against IMNV-induced disease was conferred by 
dsRNA designed to target a protein-encoding region of the 5’-most end of the IMNV 
genome, dsRNA95-475.  This region encompasses Protein 1 and the N-terminal portion 
of Protein 2 (FIGURE 2). The precise function of these peptides is unknown, other than 
that Protein 1 contains a dsRNA binding motif that is postulated to play a role in host 
immune suppression.24 Protein 1 may be a crucial gene involved in viral pathogenesis 
within the host, a factor necessary for early viral replication, or a protein that modifies the 
host RNAi antiviral response.  By analogy, Drosophila C virus and Flock House Virus 
are pathogenic RNA viruses of other invertebrate species that encode proteins that have 
dsRNA binding activity and the capacity to modify or inhibit the host RNAi response12,28.  
Protein 1 of IMNV may be fulfilling a similar role in facilitating virus replication by 
suppressing host RNAi machinery.   
Additionally, the accessibility of the targeted portion of the genome to RNAi may 
be enabling this RNA to more efficaciously inhibit viral genome replication. Significant 
factors associated with impeding target RNA accessibility include RNA secondary 
structure and protein occupancy.15 A study examining small hairpin RNA vectors 
(shRNAs) targeting conserved portions of the hepatitis B virus genome, found several 
highly effective targets in a 5’ portion of the genome.  These 5’ targets are much more 
effective than was predicted because this region contains a highly structured stem-loop, 
perhaps owing to availability according to genome location.23 
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Length Dependency 
These data demonstrate that by optimizing RNAi targets, beginning with larger 
sequences and moving through gradual truncations, the protective effect of dsRNA, on a 
per molecular weight basis, increases.  However, in the context of the RNAi capacity of a 
shrimp, a sequence length of greater than 50 base pairs (bp) may be a minimum length 
requirement, because reduction in survival was observed when the 194-275 (81 bp) 
dsRNA was truncated to 219-275 (56 bp).   This optimum threshold size of the dsRNA 
corresponds well to a recently published study that suggests that an RNAi trigger in L. 
vannamei has to be greater than 50 bp in length to stimulate transcription of the LvSid-1 
gene, which encodes the membrane-forming protein gene involved in dsRNA transport 
into cells, and that 50 bp is the lower threshold for a dsRNA to stimulate transcript 
suppression11.  In addition, a dsRNA shorter than 50 bp that corresponded to an 
endogenous shrimp mRNA CDP (shrimp transcript of unknown function) did not 
stimulate a reduction in transcript in other tissues.11   Further, dsRNA corresponding to 
WSSV genes that were shorter than 50 bp did not elucidate protection from virus 
challenge.11 
Long Term Protection 
The overall data strongly suggest that exposure to the optimized dsRNA produces 
long-term, specific immunity to subsequent challenge with a single dose as compared to 
siRNAs that require repeat injections to effect virus clearance.32 For example, animals 
subjected to a low dose of dsRNA, and challenged 10 days later demonstrated significant 
protection against IMNV disease.  To further study this phenomenon, animals were re-
challenged with IMNV following the initial dsRNA administration and challenge.  
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Animals that were subjected to a second virus challenge demonstrated high survivorship, 
even when given much higher doses of virus and after extended periods of time following 
initial dsRNA administration. This observation suggests that RNAi may serve as a 
pseudo memory-type response that provides long-term protection from IMNV infection 
in shrimp. This may also be an indication that once animals are able to initially overcome 
an IMNV challenge, they are resistant to subsequent challenges.  RNAi may be a 
mechanism that is utilized by the animal to adapt to new viral pathogens and establish 
resistance to viral replication.  This may also help to explain why in field observations, 
gross lesions of IMN appear to occur concurrently with periods of high environmental 
stress on animals, such as occurs with high stocking densities or longer grow out 
periods.2 
Sequence-Independent Effects 
Non-specific dsRNA that was generated to a heterologous target (eGFP) did not 
have a positive impact on survival in animals challenged with IMNV, in contrast to what 
has been described with other shrimp viruses including TSV, YHV and WSSV 17,19,31,33. 
Heterologous dsRNAs for avian and mammalian immunoglobulin, fish non-coding 
dsRNA, and bacterial plasmid provided moderate protection against subsequent infection 
(2 pr 3 days) with TSV or WSSV.19 Limited protection also was conferred in animals 
injected with dsRNA corresponding to GFP then infected with YHV. However, this 
effect was not observed in these studies because no degree of protection from virus 
challenge was observed in animals pre-injected with dsGFP, even when virus challenge 
occurred 2 days post dsRNA administration.  This may be due to differences in 
pathogenesis or viral replication mechanisms that IMNV utilizes.  Additionally, this 
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phenomenon may also be explained by differences in genome size; IMNV has a small 
genome relative to WSSV and TSV, and thus it may have fewer off-target sequences with 
significant homology to the control dsRNA sequences that are capable of providing this 
apparent non-specific protection. 
Here we describe a process of defining IMNV genome dsRNA targets that 
provide shrimp protection from virus challenge.  Optimization of target specificity, 
nucleotide length and dsRNA dosage level are key elements that support the potential 
economical use of RNAi triggers to protect shrimp from viral pathogens.  Targets 
identified in this manner could be utilized in downstream efforts to develop therapeutics 
or vaccines for shrimp viral pathogens, either newly emerged or pre-existing.  
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TABLE 1.   Oligonucleotide primer sequences used for dsRNA generation, initial 
cloning, and qRT-PCR.  T7 promoter sequences are underlined. 
dsRNA  Sequence 5’-3’ 
IMNV95T7F TAATACGACTCACTATAGGGAGAAGAAAGTTTGTTTCGTAGAGC 
IMNV474T7R TAATACGACTCACTATAGGGAGAAAAGGTGGCAGGTGTCCATAC 
IMNV3764T7F TAATACGACTCACTATAGGGAGAAATTTGGGTGGTTGGGACACA 
IMNV4805T7R TAATACGACTCACTATAGGGAGACCCGACTTTCGTGCACAC 
IMNV5518T7F TAATACGACTCACTATAGGGTCAACTCACTCGCAGCTGAAG 
IMNV6391T7R TAATACGACTCACTATAGGGAATATAGCAACGTCGTCTCCG 
IMNV193T7F TAATACGACTCACTATAGGGAAAACCGGAGCTGACCACATTCCA 
IMNV194T7F TAATACGACTCACTATAGGGAAACCGGAGCTGACCACATTCCAA 
IMNV275T7R TAATACGACTCACTATAGGGACTGTGTCACATGTTGCTGCTTCG 
IMNV223T7F TAATACGACTCACTATAGGGACTGTATTGGTTGAGTTCGCAGG 
IMNV376T7R TAATACGACTCACTATAGGGCTGGAGGTGGCAGCATACAAT 
IMNV219T7F TAATACGACTCACTATAGGGCTGGACTGTATTGGTTGAGTTCGC 
IMNV273T7R TAATACGACTCACTATAGGGTGTGTCACATGTTGCTGCTTCGCT 
eGFPT7F TAATACGACTCACTATAGGGAGAATGGTGAGCAAGGGCGAGGAGCTGT 
eGFPT7R TAATACGACTCACTATAGGGAGATTACTTGTACAGCTCGTCCATGCCG 
Cloning   
IMNV95F AGAAAGTTTGTTTCGTAGAGCGAGA 
IMNV474R AAAGGTGGCAGGTGTCCATACTGA 
IMNV3764F AATTTGGGTGGTTGGGACACATGG 
IMNV4805 R CCCGACTTTCGTGCACACAACTTT 
IMNV5518F TCAACTCACTCGCAGCTGAAGGTA 
IMNV6391R AATATAGCAACGTCGTCTCCGCGT 
qRT-PCR   
IMNV412F GGACCTATCATACATAGCGTTTGCA 
IMNV545R AACCCATATCTATTGTCGCTGGAT 
IMNVP1 (6FAM) CCACCTTTACTTTCAATACTACATCATCCCCGG (TAMRA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 72 
 
 
FIGURE 1. Shrimp survival post challenge with serial dilutions of a stock viral 
clarification (containing ~3.2 x 105 IMNV copy numbers/µL RNA) of infectious 
myonecrosis virus. Shrimp weighing 8-10 grams were injected with 100 µL of 
clarification into the third abdominal segment. n=20 shrimp for each viral challenge dose 
administered.     
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FIGURE 2.  Diagram of the IMNV genome transcription and translation products 
(modified from Nibert (2007) Journal of General Virology) showing regions targeted for 
RNAi.   Predicted protein products are indicated by dark gray lines (Proteins 1-3) or gray 
shading (major capsid protein and RNA-dependent RNA polymerase).   Target regions 
for dsRNA production are indicated as thick black lines with corresponding nucleotide 
regions.  Longer length dsRNAs that were generated to the region encoding Protein 1 and 
2 included two iterations truncated by ~100 bp on either side (194-475 and 95-376).  
Shorter dsRNAs generated within the Protein 1 encoding region are magnified (bottom 
left) 
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FIGURE 3.  Shrimp survival post administration with dsRNA corresponding to different 
viral gene targets and post IMNV infection.  Animals were inoculated with 2.0 µg 
dsRNA at day 0.  Animals were challenged with 100 µL of the 1:100 dilution at day 2. 
Positive control animals received an inoculation containing an equivalent volume of 
RNase free water at day 0.    Negative control animals received an equivalent volume of 
2% saline (viral diluent) on day 2. The dsRNA target position on the IMNV genome or 
heterologous dsRNA (eGFP) is indicated in the key.  X-axis indicates days post dsRNA 
administration.  Y-axis indicates percent survival.  3 replicates of 20 animals (n=60) 
weighing 5-7 grams were used for each treatment group.  
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FIGURE 4.  Viral copies calculated by Quantitative Reverse Transcription Polymerase 
Chain Reaction (qRT-PCR) in muscle tissue at day 9-12 post challenge.  X-axis is 
treatment and Y-axis is log viral genome copy number.  Bars represent standard error 
within the sample.   
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FIGURE 5.   A) Shrimp survival post administration with dsRNA 95-475 and post IMNV 
infection.  Animals were inoculated with 2.0 µg, 0.2 µg, or 0.02 µg dsRNA at day 0 and 
were challenged at day. X-axis indicates days post dsRNA administration.  Y-axis 
indicates survival.  10.B) Shrimp survival post administration with dsRNA 3764-4805 
and post IMNV infection. Animals were inoculated with 2.0 µg, 0.2 µg, or 0.02 µg 
dsRNA at day 0 and were challenged at day 10. C) Shrimp survival post administration 
with dsRNA eGFP and post IMNV infection.  Animals were inoculated with 2.0 µg 
dsRNA at day 0 and were challenged at day 10. D) Survival of all treatment groups at 
termination of study (Day 40).  Positive control animals received an inoculation 
containing an equivalent volume of RNase free water at day 0.    Negative control 
animals received an equivalent volume of 2% saline (viral diluent) on day 10. X-axis 
indicates treatment.  Y-axis indicates number of survivors at termination. 10 animals with 
weights of 3-5 grams were used for each treatment (n=10) 
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FIGURE 6.  A) Shrimp survival post administration with initial dsRNA truncations of 95-
475, 193-475, and 95-376 and post IMNV infection.  Animals were inoculated with 0.02 
µg dsRNA at day 0 and were challenged at day 10. X-axis indicates days post dsRNA 
administration.  Y-axis indicates percent survival. B) Shrimp survival post administration 
with further truncations of dsRNA 223-376, 194-275, or 219-273  and post IMNV 
infection. Animals were inoculated 0.02 µg dsRNA at day 0 and were challenged at day 
10. C) Shrimp survival of positive or negative controls and post IMNV infection. Positive 
control animals received an inoculation containing an equivalent volume of RNase free 
water at day 0 and viral challenge on day 10.  Negative control animals received an 
equivalent volume of 2% saline (viral diluent) on day 10. D) Survival of all treatment 
groups at termination of study (Day 30). X-axis indicates treatment by dsRNA fragment 
length.  Y-axis indicates number of survivors at termination. 3 replicate tanks of 10 
animals weighing 3-5 grams were used for each treatment (n=30) except the negative 
control which had a single tank (n=10). 
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Abstract 
Infectious myonecrosis virus (IMNV) is a significant and emerging pathogen that 
has a tremendous impact on the culture of the farmed Pacific white shrimp (Litopenaeus 
vannamei).  IMNV first emerged in Brazil in 2002 and subsequently spread to Indonesia 
causing large economic losses in both countries.  No existing therapeutic treatments or 
effective interventions currently exist for IMNV.  RNA interference (RNAi) has been one 
effective strategy developed to prevent viral disease in shrimp.  Here we describe the 
efficacy of a dsRNA applied as an antiviral therapeutic following viral challenge.  The 
antiviral therapeutic used was a sequence-optimized dsRNA construct targeting a viral 
sequence encoding dsRNA binding motifs, that had previously showed outstanding 
antiviral protection when administered prior to infection.  Our data indicates that at least 
50% survival can be attained with low doses (0.5 µg) of dsRNA if administered 48 hours 
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following an infection with an otherwise lethal dose of IMNV, and that this degree of 
protection was not observed when dsRNA was administered 72 hours post infection.   
Additionally, the administration of this antiviral demonstrated a significant reduction in 
viral loads in the muscle of animals that died from disease or survived until termination 
of the study as assessed by quantitative RT-PCR.   This data indicates that a sequence and 
length optimized RNAi antiviral molecule holds promise for use as an antiviral 
therapeutic against IMNV.   
Introduction 
Infectious Myonecrosis (IMN) is a severe and emerging shrimp disease that was 
first described in 2003 after a severe outbreak in northeastern Brazil characterized by 
high mortality and animals exhibiting necrosis in the tail muscle.12 The etiologic agent is 
a non-enveloped, double-stranded RNA (dsRNA) virus that is a member of the 
Totiviridae family, subsequently named Infectious Myonecrosis Virus (IMNV).  IMNV 
was discovered in Indonesia in 2006;16 and is causing tremendous impact on the shrimp 
industry within the country. During outbreaks of IMNV, mortality has ranged from 40% 
to 70% prior to harvest and causes a dramatic increase in feed conversion.1 IMNV 
outbreaks have been found to be associated with longer growout periods and higher 
stocking densities following an epidemiological survey of risk factors.2 The insidious 
presentation of this disease, resulting in a gradual loss of animals over duration of the 
growout period, makes IMNV an excellent target for a therapeutic agent, as treatments 
could be initiated immediately following a diagnosis of IMNV within a pond.  
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RNA interference (RNAi) is one possible and promising method to mitigate viral 
disease in shrimp.7,9,13,14,17   RNAi has been used to prevent shrimp viral diseases caused 
by White Spot Syndrome Virus (WSSV)13,22 Yellowhead Virus (YHV),19,20,23 Taura 
Syndrome Virus (TSV),15 Penaeus stylirostris densovirus (PstDNV) (formerly called 
infectious hypodermal and hematopoietic necrosis virus (IHHNV)),8 and IMNV.11 In 
addition to administration prior to viral exposure, the therapeutic effect of RNAi has been 
tested against many different RNA and DNA viruses of animals and humans, several of 
which are being evaluated in Phase 1 and 2 human clinical trials as antiviral therapeutics.5 
In shrimp, a therapeutic effect has been described against WSSV22 and YHV20 post 
dsRNA inoculation. Some evidence indicates that dsRNA administration and induction of 
RNAi pathways may allow for clearance of virus in shrimp naturally-infected with 
Penaeus monodon densovirus (PmDV).3 Recently described methods allow for a 
sequence and length optimized construct to be developed against a specific shrimp 
pathogen.11 The objective of these experiments was to test the therapeutic efficacy of a 
sequence-optimized dsRNA construct that showed outstanding protection when 
administered prior to infection (Loy et al. 2011), in the face of an active IMNV infection.    
Materials and Methods 
Animal Rearing 
Specific pathogen free (SPF) L. vannamei postlarvae were received from Shrimp 
Improvement Systems (Plantation Key, Florida) and reared in a biosecure animal holding 
facility at Iowa State University.   Animals were placed into 1000 L tanks containing 
artificial seawater (Crystal Sea Marine Mix) at 25 ppt salinity, an oystershell airlift 
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biofilter, and an activated carbon filter.  Temperature was maintained at 30º C.  Animals 
were fed a commercial growout diet (Rangen 35/10, Buhl, Idaho) until 3-5 grams in 
weight.    
Preparation of Viral Inoculum 
Based on a previously described methodology6, tissue macerate from infected 
animals (that tested negative for other shrimp viruses by PCR) was diluted 1:3 in TN 
buffer (0.02 M Tris-HCL, 0.4 M NaCL, pH 7.4) and clarified through three centrifugation 
steps after each of which supernatant was removed: 1) 4000 x g for 30 min, 2)15,000 x g 
for 15 min 3) 25,000 x g for 60 min.   The final supernatant was diluted 1:10 in sterile 2% 
NaCl and passed through a 0.2 micron filter.   This stock viral clarification was aliquoted 
and frozen at -80º C.  Quantitative RT-PCR analysis of RNA extracted from a freeze-
thaw indicated 105 viral copy numbers/µl were present in the stock.   
Determination of Challenge Dose 
The optimum lethal dose by injection resulting in infection and disease was tested 
in SPF L. vannamei weighing 8-10 g and described in detail by Loy et al.11 Briefly, each 
animal was injected with 100 µl of a 1:100 dilution of viral clarification into the third 
abdominal segment, a dose which resulted in 100% mortality at 18 days post infection 
(dpi).  
Quantitative Reverse-Transcription PCR 
Quantitative Reverse-Transcription PCR (qRT-PCR) was performed using 
methods adapted from Andrade et al.1  Briefly, 30 mg of macerated muscle tissue and 
homogenized using a QIAShedder column (Qiagen) followed RNA extraction with an 
RNeasy Minikit (Qiagen). RNA template (50 µl) was eluted from the column into RNase 
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free water and stored at -80º C until the RT-PCR was performed. qRT-PCR templates 
were thawed and boiled at 100ºC for 5 min prior to reverse transcription. RNA template 
(2 µl) was mixed with 5 µl of 5x One Step RT-PCR Master Mix (Qiagen), 1 µl Enzyme 
Mix, 1 µl DNTP, 0.3 µl IMNV412 (20 uM) (5′-GGA CCT ATC ATA CAT AGC GTT 
TGC A-3′), 0.3 µl IMNV312R (20 uM) (5′-AAC CCA TAT CTA TTG TCGCTGGAT-
3′), 0.3 µl IMNV p1 (10 uM) (5′-6FAM CCA CCT TTA CTT TCA ATA CTA CAT 
CAT CCC CGG TAMRA-3′) and 15 µl RNase free water for a total reaction volume of 
25 µl.  This reaction was then run in duplicate or triplicate on a BioRad CFX96 Real 
Time PCR Detection System under the following conditions: RT for 30 min at 48°C and 
10 min at 95°C, followed by PCR for 35 cycles of 15 s at 95°C and 1 min at 60°C.  Viral 
copy number was calculated using CFX Manager Software (BioRad) using an in vitro 
transcribed RNA standard generated using methods from Andrade et al.1 
dsRNA Preparation 
dsRNA was prepared using Ambion Megascript RNAi Kit following the  
manufacturer’s directions. To create template for dsRNA synthesis, RNA was extracted 
from virally infected animals using a commercial nucleic acid purification kit (Qiagen 
RNeasy Mini).  Oligonucleotide primers for cDNA synthesis were then designed 
sequence available (GenBank accession no.EF061744)16 (TABLE 1). Reverse 
transcription of RNA was performed using Thermoscript RT per manufacturer’s 
instructions (Invitrogen).  Following reverse transcription, template cDNA (~50 ng, not 
calculated) was added to a PCR master mix (PuReTaq Ready-To-Go PCR Beads) and 
thermal-cycling was performed using oligonucleotide primers (TABLE 1) designed to 
specific regions of the IMNV genome (GenBank accession EF061744.1).  Products were 
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then cloned into pCR4.0 vectors (Zero Blunt TOPO PCR cloning kit) and transformed 
into E. coli (TOP10 Invitrogen).  Plasmids preparations from these transformants were 
used as a template source for further PCR reactions to create DNA clones for RNA 
transcription   For synthesis of template for transcription, primers containing a T7 
promoter sequence (TABLE 1) on the forward and reverse primer were used to amplify 
the segments of cDNA with flanking T7 promoter sites.  T7 DNA templates were then 
transcribed overnight (16 hours) following the manufacturer’s directions. Following 
transcription, dsRNA products were incubated for 60 minutes with DNase I and RNase, 
and purified using the provided columns.  Transcription of dsRNA was confirmed by gel 
electrophoresis in comparison with a molecular weight ladder (pGEM ladder, Promega) 
and product was quantified by spectrophotometer.  
Histopathology  
Moribund animals that were found prior to death were fixed in whole Davidson’s 
fixative4 for 24 hours before being transferred to 70% EtOH before embedding in 
paraffin. Two animals from each tank were anesthetized in an ice slurry and fixed in 
Davidson’s fixative4 embedded in paraffin, cut into slides and stained with hematoxylin 
and eosin and evaluated for the presence of IMNV lesions. 
Statistical Analysis 
End points of mean survival was analyzed using One-way ANOVA followed by 
Tukey’s multiple comparison test using JMP 8 software.  Mean log viral copy numbers 
ran in triplicate were normalized and then compared following using One-way ANOVA 
followed by Tukey’s multiple comparison test using JMP 8 software 
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Shrimp Bioassays 
Tanks containing 200 L synthetic seawater and an oystershell airlift biofilter tanks 
were stocked with 10 SPF juveniles weighing 3-5 g and allowed to acclimate for 72 h.  
Tanks were randomized and three replicates were assigned for each treatment.  Following 
acclimation animals were challenged by injection into the third abdominal segment with 
lethal dose of IMNV.   Forty eight hours later a total of 5.0 µg of in vitro synthesized 
dsRNA was inoculated into animals that had been challenged with IMNV.  Sham 
treatment groups received an equivalent volume of RNase free water.  Sham challenge 
(negative) groups received an equivalent volume of 2% NaCl (viral diluent). Animals 
were counted daily for mortality and assessed for clinical signs.  Moribund animals that 
were found were fixed for histopathology. At termination 2 animals from each tank were 
fixed and submitted for histopathological examination. Dead animals removed 
throughout the experimental period were frozen at -80ºC.   
Dose/Duration Bioassay 
Tanks were challenged with IMNV virus simultaneously with groups receiving 
treatments at 24, 48, or 72 h.   Treatment groups consisted of either 5.0 or 0.5 µg of in 
vitro synthesized dsRNA 194-475, 5.0 µg of eGFP dsRNA, or a sham treatment of an 
equivalent volume of RNase free water at an equivalent volume and time interval.  Sham 
challenge (strict negative) groups received an equivalent volume of 2% NaCl (viral 
diluent).  
Results 
A disease challenge model was established that uses an intramuscular injection of 
a clarified virus preparation that resulted in 100% mortality within 18 d, using a 100-fold 
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dilution of the tissue homogenate (~3.2 x 103 IMNV copy numbers/µl RNA Specific 
pathogen free (SPF) L. vannamei (3-5 g in weight) were subjected to a lethal 
intramuscular challenge and 48 h later to a single dose containing 5.0 µg of dsRNA194-
275 demonstrated 50% survival.  By comparison animals that received the same dose of 
eGFP dsRNA (dseGFP) or the equivalent volume of RNase free water showed 100% 
mortality following challenge (FIGURE 1).   Significant differences (P=0.007) in 
survivorship were evident between the experimental and control groups. 
Viral Copy Number Quantification 
Differences in virus genome copy number were assessed via qRT-PCR on muscle 
tissues sampled from dead animals at 8-12 d post-infection or at the termination of the 
study. A significant reduction (P=0.01) in viral copy number was evident between 
animals administered 5.0 µg dsRNA194-275 that either succumbed to disease or survived 
until termination (P<.0001) (mean 5.84 x 105 and 4.87 x 104 IMNV copy numbers/µl 
RNA, respectively), when compared with animals that received 5.0 µg of eGFP dsRNA 
or RNAse free water. 
Dosage and Temporal Effects 
To further characterize the observed therapeutic response, the temporal effects 
and dose response factors that influence a successful IMNV therapeutic treatment were 
tested. Animals treated 24 h after viral challenge demonstrated 60% survival after 
treatment with 5.0 µg dsRNA (high dose) as compared to 50% survival in the animals 
treated with 0.5 µg dsRNA (low dose) (FIGURE 3).  Control animals that received 5.0 µg 
heterologous dsRNA eGFP (dseGFP) demonstrated 30% survival and the RNase free 
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water injected animals showed 0% survival.  Animals treated 48 hours post-challenge 
demonstrated 90% survival in the high dose treatment group and 50% survival in the low 
dose group with 0% survival in groups receiving dseGFP and 20% survival in the RNase 
free water injected group (FIGURE 4).  Experimental and control groups showed 0% 
survival when dsRNA was provide 72 h post-infection (FIGURE 5). 
Gross Lesions 
Animals in each treatment group were examined for gross lesions daily.  Presence 
of gross lesions was evident as single or multiple foci of opacity within the tail muscle.  
All individuals in all challenged groups developed a focal or multi-focal muscle tissue 
opacity by day 5 post challenge.  Several individuals treated with dsRNA194-275 in the 
48 h post challenge had opacities resolve by 12 days post challenge (FIGURE 6).  
Lesions in untreated animals did not resolve, and all of these animals succumbed to 
death.   
Histopathology 
Acute histopathologic lesions were characterized by coagulative necrosis and 
fragmentation of muscle bundles with edema prominent within the muscle bundle sheaths 
and between affected muscle bundles. Infiltration of hemocytes was mostly limited to 
small clusters scattered along the connective tissue septa that separated groups of 
muscles. Chronic lesions were characterized by partial or total loss of myofibers with 
condensation/contraction of the fibrous connective tissue components. These lesions 
correspond with characteristic histopathological changes typically seen with IMNV 
infection.11,12  
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Moribund animals that were found in tanks were sampled from sham-vaccinated 
controls (7 animals), eGFP dsRNA administered controls (3 animals), and animals treated 
with dsRNA 194-275 (4 animals).  Additionally, 2 animals from each tank were sampled 
from surviving animals at the termination of the study (9 animals). Histopathological 
lesions in moribund animals in animals from all groups were characterized predominantly 
by extensive fibrosis occasionally with concurrent acute coagulative necrosis. Acute 
necrosis without chronic lesions was evident in only one animal. Animals treated with 
dsRNA 194-275 that survived until termination of the study had chronic resolving lesions 
that varied from extensive fibrosis (2 animals) to scattered small foci of fibrosis (3 
animals) or no significant lesions present (3 animals). No acute lesions were seen in any 
of these longer-surviving treated animals. 
Discussion  
These studies describe the first use of RNAi to treat disease in shrimp infected 
with IMNV, a significant emerging shrimp pathogen. Previous data demonstrated that a 
very specific short dsRNA confers robust and long-term resistance to IMNV-induced 
disease and mortality when administered prior to viral infection.11 These experiments 
demonstrate that the same short dsRNA can also therapeutically treat animals with pre-
existing viral infections.  Additionally, it was noted that non-sequence specific dsRNA 
administered at high dosage levels (5.0 µg) does not induce a protective response when 
administered therapeutically at 48 hours post-infection.  This is similar to previous 
findings that showed no positive effect on survival when dseGFP was administered 
prophylactically.11 Demonstrating therapeutic efficacy is a significant step towards 
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developing an antiviral therapeutic for infected animals as part of a disease control 
program. Such a protocol could help to eliminate or reduce IMNV loads in infected 
ponds.   
In order to determine threshold therapeutic doses of dsRNA and simultaneously 
characterize the temporal activity of the RNAi response, animals were administered two 
doses levels of dsRNA (0.5 or 5.0 µg).   Significant differences in survival were apparent 
at both doses, when given either 24 or 48 h post-virus exposure. This is similar to 
findings using IMNV specific dsRNA delivered prior to infection, where doses as low as 
20 ng protected animals from succumbing to IMNV disease11 and such a protocol may 
help eliminate or reduce IMNV loads in infected ponds.   
 Dose and Temporal Response  
Low dosage levels appear to provide protection in animals early in the disease 
process.   By contrast, when dsRNA 194-275 was administered 72 h post-challenge, no 
survival-enhancing effect was observed.  This may be due to a significant amount of viral 
replication taking place between 48 h and 72 h, where the amount of virus replication that 
has occurred likely exceeds the capacity of an RNAi antiviral effect.  Prior work 
examining the therapeutic effect of dsRNA on survival of shrimp from YHV or PstDNV 
challenge has been demonstrated only at higher dosages and shorter intervals (3 or 12 h 
post infection at a 25.0 µg dose dsRNA20 or 24 hours post infection with a 5.0-12.5 µg 
dose dsRNA)8. No experimental studies have examined the replication dynamics of 
IMNV in shrimp, but these data suggest that a large amount of virus replication is 
occurring between 48 and 72 hours post infection, and after which time animals are 
refractory to treatment with specific dsRNA.   
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This temporal phenomenon may also be explained by the target sequence of this 
dsRNA, a cleavage product called “Protein 1” that contains a dsRNA binding motif.18  
This protein may be involved in suppression of host cellular RNAi responses or innate 
immunity during early viral replication. Viral proteins with dsRNA binding activity have 
been described and characterized as inhibiting the RNAi machinery such as Drosophila C 
virus (DCV) and Flock House virus (FHV).21,10 If this putative dsRNA binding protein, 
indeed suppresses an element of the RNAi machinery and it were expressed to a high 
degree in a large number of infected cells, the ability for the host to elicit an appropriate 
antiviral RNAi response would be impeded.   Further studies into the role of this dsRNA 
binding protein and the role it may play in immune suppression of the host and 
pathogenesis during IMNV infection are warranted.   
The use of a small and optimized dsRNA sequence and the ability of this 
sequence to be used as an antiviral therapeutic for IMNV in L. vannamei was 
demonstrated.  Small amounts (0.5 µg) of IMNV specific dsRNA can prevent mortality 
in animals with active viral infection. RT-PCR diagnostic methods have been developed 
that would allow for a rapid turnaround for a diagnosis.1 If feasible delivery methods for 
dsRNA in shrimp ponds become available, a therapeutic treatment of small, targeted 
dsRNA could provide mitigation of viral disease losses in virus-infected animals.  
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TABLE 1.  Oligonucleotide primer sequences for dsRNA synthesis, cloning and qPCR 
Primer  Sequence 5’-3’ Source 
IMNV194T7
F 
TAATACGACTCACTATAGGGAAACCGGAGCTGACCACA
TTCCAA 
Loy et al (2011) 
IMNV275T7
R 
TAATACGACTCACTATAGGGACTGTGTCACATGTTGCTG
CTTCG 
Loy et al (2011) 
eGFPT7F TAATACGACTCACTATAGGGAGAATGGTGAGCAAGGGC
GAGGAGCTGT 
Loy et al (2011) 
eGFPT7R TAATACGACTCACTATAGGGAGATTACTTGTACAGCTCG
TCCATGCCG 
Loy et al (2011) 
IMNV95F AGAAAGTTTGTTTCGTAGAGCGAGA Loy et al (2011) 
IMNV474R AAAGGTGGCAGGTGTCCATACTGA Loy et al (2011) 
IMNV412F GGACCTATCATACATAGCGTTTGCA Andrade et al 
(2007) 
IMNV545R AACCCATATCTATTGTCGCTGGAT Andrade et al 
(2007) 
IMNVP1 (6FAM) CCACCTTTACTTTCAATACTACATCATCCCCGG 
(TAMRA) 
Andrade et al 
(2007) 
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FIGURE 1.  (Left) Percent survivorship of animals that were infected with a lethal 
dose of IMNV (day 0), then injected with dsRNA194-275 at 48 h post-challenge.  
Animals were observed for 20 d post-infection.  n=30 animals with 3 replicate tanks of 
10 animals per treatment.  
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FIGURE 2. Virus copy number, as determined by quantitative RT-PCR, in muscle tissue 
from IMNV-infected L. vannamei that were provided with dsRNA treatment or control 
conditions.   Muscle issues were collected from dsRNA194-275 survivors (Survivors) 
that survived and were sacrificed at day 20 post challenge.  For the dsRNA 194-275 
Mortalities, Sham, and dseGFP groups, samples were collected from dead or moribund 
animals from day 9-14 post challenge. Y-axis indicates mean log viral copy number 
calculated on The y-axis indicates log viral genome copy number calculated from an 
RNA standard curve generated per (Andrade et al 2007).  Bars represent standard error 
within the sample. n=6 animals per group.  
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FIGURE 3.  Percent survivorship of animals following injection challenge with IMNV 
inoculum and treatment by injection of dsRNA after 24 hours.  X-axis is days post 
challenge.  Y-axis is percent of animals surviving.  Sham animals received an equivalent 
dose of RNase free water and negative control animals were sham challenged with an 
equivalent dose of sterile 2% NaCl. 
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FIGURE 4.  Percent survivorship of animals following injection challenge with IMNV 
inoculum and treatment by injection of dsRNA after 48 hours.  X-axis is days post 
challenge.  Y-axis is percent of animals surviving.  Sham animals received an equivalent 
dose of RNase free water and negative control animals were sham challenged with an 
equivalent dose of sterile 2% NaCl. 
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FIGURE 5. Percent survivorship of animals following injection challenge with IMNV 
inoculum and treatment by injection of dsRNA after 72 hours.  X-axis is days post 
challenge.  Y-axis is percent of animals surviving.  Sham animals received an equivalent 
dose of RNase free water and negative control animals were sham challenged with an 
equivalent dose of sterile 2% NaCl. 
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FIGURE 6.  Images of gross lesions of the same shrimp abdomen taken on d 4 post 
challenge (Left) and d 12 post challenge (Right).  Focal to multifocal muscle opacities 
were observed 4 d post challenge and 2 d post dsRNA194-275 administration.  Gross 
lesions were not apparent in animals administered dsRNA at 12 d post challenge and 10 d 
post dsRNA administration 
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CHAPTER 5: GENERAL CONCLUSIONS 
 
 
The results from this work substantiate the idea that the white leg or Pacific white 
shrimp, Litopenaeus vannamei, possess a complex immune system capable of specifically 
recognizing and responding to insults from viral pathogens.  Moreover, that this immune 
system can be primed or modulated using very small quantities of exogenous double 
stranded RNA to mount a highly specific, long-lasting, and effective response.  Although 
the mechanisms underlying this response are not well understood, they are likely to be 
evolutionarily and fundamentally distinct from the specific and adaptive humoral 
responses observed in vertebrate immune systems.  Akin to the adaptive response, the 
shrimp immune response is functionally capable of eliciting a specific and robust 
response to viral disease that is functional for extended periods of time, and often that 
amount to a significant portion of the organism’s lifespan.   These observations are 
suggestive of much more complex immune system, one that is distinct from general non-
specific innate immunity that is responsive in a generic manner and short-lived.  The data 
presented herein point to RNA interference (RNAi) as a primary antiviral response 
underlying this long-term immunity.  The RNAi antiviral response diverges from the 
common understanding of proteins as long-term immune response elicitors, the hallmark 
of “specific” immunity, in that it has instead diverged to recognize nucleic acids, and 
specific sequence components of those nucleic acids that are produced during a viral 
infection.  In this sense, marine shrimp antiviral immunity is, at many levels, challenging 
the current paradigms of immunity.  This dissertation further expands that body of 
research.   
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 Specifically, it was observed for the first time in shrimp that very small 
amounts (20 nanograms) of a precisely targeted dsRNA that elicits an RNAi response can 
protect animals (100% survival vs. 0% survival) for at least ten days, and likely longer.   
This is a 100% increase over previously described periods of protection (5 days vs. 10 
days) and a 1000-fold lower dose that had been used to demonstrate protection in 
previous studies.3 Additionally, shrimp that were subjected to this dsRNA construct then 
exposed to IMNV, were resistant to subsequent challenges (of 100x higher dosage of 
virus) for at least 90 days. This same molecule could not only prevent, but also 
therapeutically treat infections existing infections up to 2 days after receiving a lethal 
dose of virus.  These results indicate that the RNAi antiviral immune response in a 
shrimp is significantly more potent and longer lasting than had previously been thought.   
Several new tools and methodologies were also developed and explored in this 
dissertation that will enable future work to develop disease control technologies. We 
developed a concept viral genome panning to develop the most effective antiviral effector 
molecules is also a novel concept to fight shrimp diseases.  Previous work had targeted 
only a handful of sequences or gene targets against each virus (1 or 2 sequences per 
virus).  This work demonstrates that even within a very small virus such as IMNV (~7500 
bp) there are extreme differences observed in survival between the viral sequences 
targeted (0% vs 100%) and that panning the genome to discover the most protective 
sequences is a prudent means to develop an antiviral prophylactic.   From a production 
standpoint it was also determined that smaller molecules can also be as effective or more 
effective than longer ones (80 bp vs. 500 bp) thereby facilitating more efficient 
production.   Additionally, this work also has large implications to developing therapeutic 
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drugs for shrimp and other invertebrates, because the sequences used to develop antiviral 
molecules also demonstrated efficacy as a therapy against a pre-exsisting infection.   
A lack of in vitro tools to explore and mechanistically define the shrimp immune 
system impedes research into the pathways responsible for the immune phenomena.  Not 
only are marine shrimp a model for a fundamental understanding of invertebrate 
immunity, but they are of great commercial importance as well.  Shrimp culture is rapidly 
growing, is of tremendous economic importance to many developing countries, and 
shrimp products are in high demand by consumers.  Shrimp production is plagued by 
viral disease, and limited research and knowledge into the immune response has 
generated a tremendous deficit in knowledge about the shrimp response to pathogens.  
Unfortunately, the creation of immortal cell culture lines from marine invertebrates has 
continued to elude researchers.  Therefore, studies on pathogen-shrimp interaction must 
be done in vivo using reliable and repeatable disease challenge models.  The work 
outlined in this dissertation establishes repeatable disease models for a bacterial pathogen 
as well as a newly emerged viral disease of marine shrimp, to enable such research in 
vivo until such in vitro tools are developed. Having a repeatable challenge model and 
propagation system available for NHP, it is now possible to propagate enough organisms 
to study these primitive bacteria at a more fundamental level.  Currently, only one 
sequence is available for researchers in GenBank, and it would be prudent to sequence 
the genome or add to the available sequences of this organism.  The analysis of the 
available sequences suggest that it is a unique and early form of proteobacteria, and 
sequencing of the NHPB genome may prove not only useful for shrimp farming, but to 
further a more fundamental understanding of the evolution of early bacterial organisms.   
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Future Directions 
With the models and strategies developed for the study of pathogens in L. 
vannamei established, the way is paved for a fundamental study of genes involved in both 
viral and bacterial pathogenesis and the host response to these pathogens.  Current 
models of the RNAi machinery and immune pathways in penaeid shrimp are based on an 
extrapolation from model systems of other invertebrate species including Caenorhabditis 
elegans or Drosophila melanogaster.  The research presented herein underscores the 
possibility that a comparatively larger and longer-lived marine arthropod has evolved 
alternative or enhanced specialized pathways to protect itself in the face of pathogens 
during the lifetime of the animal, which is significantly longer than most insects and 
nematodes.   Data presented in this dissertation show that the duration of protection 
against viral agents exceeds that previously described in other animals by weeks or more, 
and that shrimp have a robust capacity to protect themselves from virus infection for a 
significant part of its lifespan.  It may be that only during severe stress, such as what 
occurs at high stocking densities and feeding rates, that viruses overcome this immune 
response and manifest in disease, similar to what occurs to some degree in concentrated 
vertebrate animal feeding operations.  The ability to specifically augment this natural 
response to specific viral infections would prove a great boon to shrimp farmers 
throughout the world, who culture their animals in an environment that facilitates and 
enhances transmission of viruses and leads to devastating disease outbreaks.  Research 
should be undertaken to explore the underlying mechanisms responsible for this duration 
of specific antiviral protection, and if RNAi machinery is responsible for this “memory.”   
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The discovery process described in this dissertation for a potent and effective anti-
viral molecules that can prevent or therapeutically treat shrimp disease caused by IMNV 
is a critical step in the development of efficacious interventions that can mitigate 
significant losses producers face from this and other viruses in the field.  Lack of 
knowledge and understanding of the fundamental principles of epidemiology, 
immunology, and pathology of shrimp viral infection is evident, in that it remains 
unknown how these signals are initiated, propagated, and maintained during the lifetime 
of shrimp.    A basic understanding of these mechanisms and processes would provide a 
much-needed background into developing efficient delivery methods. In addition, the 
varying anatomic and physiologic conditions across the multiple life stages and ages in 
this species should also be taken into consideration in future mechanistic studies, because 
fundamental differences in observed responses may occur in this species with that has a  
broad range of diets and environments.  
There is an enormous amount of research needed to help mitigate the impact these 
viruses have on shrimp production.  For example, challenge models that replicate IMN 
disease dynamics within pond systems and specific triggers that induce acute mortalities 
or “breaks” in the field need to be established, in the same vein as first chapter of this 
dissertation as it relates to NHPB disease.  This would allow for interventions to be tested 
in a laboratory under simulated field conditions.  Such a model would allow study of the 
etiology and disease transmission that occurs under pond conditions and would allow 
researchers to study interventions that may reduce transmission or break disease cycles 
within culture ponds.  
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 Much of the shrimp culture employs animals derived from a small number of 
founder stocks.  Selectively bred animals do demonstrate antiviral resistance after 
multiple generations.1   The genetic basis for viral resistance should be explored because it 
could reveal new innate immune capacities to tap into for different disease control 
strategies.   Work should continue on evaluating wild stocks for genetic diversity. 
Genetic resistances to additional viruses using selection pressures on captive animals 
should be applied to develop animals that are increasingly resistant to viral pathogens and 
more amenable to intensive rearing conditions.  Furthermore, existing disease resistant 
stocks should be assessed using molecular genetics, to try and establish a genetic basis 
for immunity and/or resistance to virus induced disease.  This knowledge would certainly 
be applicable to other viruses and diseases in shrimp.   
In addition to exploiting the genetic capacity of the shrimp to mitigate disease, 
interventions must be developed that allow for efficient delivery of molecules to the 
shrimp.  Delivery systems using microparticle or nanoparticle encapsidation of nucleic 
acids to enhance or optimize delivery across the GI epithelia should be evaluated.  Proof 
of concept work described in the literature review has demonstrated that these RNA 
antiviral molecules have some degree of efficacy when delivered orally.  The next step 
should be taken to evaluate all available vectors or delivery systems to optimize and 
facilitate efficient delivery of these RNA molecules through some vehicle.   Great strides 
have been made developing complex and targeted delivery systems for RNA based 
human drug candidates; such applications of these technologies to shrimp and arthropods 
would be prudent.   
 108 
For example, the usage of viral-based delivery systems should be evaluated.  
Invertebrates are naturally infected with a wide variety of viruses, many of which, such as 
baculoviruses or alphaviruses are routinely used as laboratory expression vectors.  These 
systems should be evaluated for use in delivering nucleic acid or protein based antivirals 
to shrimp. 
   One promising concept utilizes the idea of paratransgenesis, a technique that 
involves transforming symbionts or colonizing organisms to express a gene that enables 
disease reduction or disease transmission in the host.  One example of this in shrimp used   
Artemia, a common live food source in shrimp hatcheries, as a paratransgenic vector.  
Artemia has shown to bioconcentrate transgenic algae and E. coli, and thus may be a 
vehicle to deliver those transgenic products to shrimp upon ingestion.3 The usage of a 
paratransgenic delivery system may be one method of overcoming the difficulties of 
delivering drugs in marine environments.   
In summary, the models for many infectious pathogens in vivo have been 
developed and the molecules needed to induce robust and potent antiviral responses in 
shrimp have been characterized.  Further work needs to focus on methods of delivering 
these efficiently to the animal in a cost-effective manner.  Currently, it is unclear what 
exact guise or form these delivery systems might take.  However, the scientific tools to 
forge such a delivery system exist and a focused and comprehensive research program 
will likely be able to overcome this problem in the future.   
 109 
References 
1.  Argue BJ, Arce SM, Lotz JM, Moss SM. (2002) Selective breeding of Pacific 
white shrimp (Litopenaeus vannamei) for growth and resistance to Taura 
Syndrome Virus.  Aquaculture.  204: 447-460 
2.  Bartholomay LC, Loy DS, Loy JD, and Harris DL (2011). Nucleic-acid based 
antivirals: augmenting RNA interference to ‘vaccinate’ Litopenaeus vannamei.  
Journal of Invertebrate Pathology.  In press 
3.   Subhadra B, Hurwitz I, Fleck A, Rao DVS, Rao GS, Durvasula R. (2010). 
Development of paratransgenic Artemia as a platform for control of infectious 
diseases in shrimp mariculture.  Journal of Applied Microbiology.  108: 831-840 
 
 
 
 
 110 
 
 
ACKNOWLEDGMENTS 
“The more we learn about the world, and the deeper our learning, the more conscious, 
specific, and articulate will be our knowledge of what we do not know, our knowledge of 
our ignorance. For this, indeed, is the main source of our ignorance — the fact that our 
knowledge can be only finite, while our ignorance must necessarily be infinite.” 
 
Sir Karl Popper  
Conjectures and Refutations: The Growth of Scientific Knowledge 
 
 
Firstly, I would like to thank my current and past graduate committee members 
for continued support, guidance, and mentorship.  Navigating the course through a 
graduate program is not something undertaken alone, and the graduate committee 
members have my gratitude for all of their assistance in this journey. 
  A special thanks to Dr. Bradley Blitvich for serving as my major professor and 
for all his work in helping me at such a critical time complete my graduate study.  I am 
sincerely grateful for all his assistance.   
Thank you to Dr. Bruce Janke for his eternal willingness to help me with shrimp 
histopathology, and for his assistance in development and implementation of new 
techniques for multiple organisms. Thanks to Dr. Charles Thoen, whose passion for 
microbiology and zoonoses was infectious, and your classes were some of my favorite 
and most beneficial in veterinary and graduate school.  Thank you to Dr. Joe Morris for 
sparking my interest not only in aquaculture in natural resources, but for encouraging me 
to contemplate the philosophy of science.    
 111 
I would also like to specifically thank Dr. Hank Harris for his continued support 
from undergraduate, through a very challenging Veterinary Medicine curriculum and 
concurrent PhD study, and beyond. It was through him that I was able to grasp that a 
veterinary career was not limited to practice, and that a path existed to prepare for a 
career in research. Dr. Harris was not only willing to take on and mentor a concurrent 
student, but actively supported and encouraged me in every step of the process.    The 
opportunities he has given me and my family have been enormous and the challenges 
great, and Dr. Harris has truly been a great influence and mentor in my life.   
Also I would like to include a special thank you to Dr. Lyric Bartholomay, whose 
continued mentorship has been invaluable.  I have truly become an improved writer, 
presenter, and scientist because of her countless hours of guidance.  Her collaborative 
spirit, work ethic, humor, and enthusiasm for science have inspired me, as well as 
hundreds of other students of science, greatly.  
I would like to thank both Dr. Alan Loynachan and Dr. Matthew Erdman, two 
individuals who provided much guidance, encouragement, and inspiration to complete a 
concurrent program when it seemed impossible.  Thank you to Mark Mogler and Ryan 
Vander Veen for assistance in countless ways scientifically, professionally, and 
personally.  You and your families have both been and continue to be great friends and 
colleagues and I cannot thank you enough in the space here.  Thanks to other current and 
former members of Harris Labs including the first shrimp engineer I had the pleasure to 
work with, Zachary Loy, Cara Loy, Sam Robinson, Andy Robinson, Brenda Crabtree, 
Kristen Baumgartner, and Stephen Gaul and all the other undergraduates who assisted me 
over the years.   
 112 
I would also like to thank Grishma Parikh, Jonathon Oliver, and Patrick Jennings 
from the Bartholomay Lab for not only opening their laboratory and office doors, but for 
putting together some great collaborative efforts.  
I would like to thank Kurt Kamrud for his continued guidance and input both 
professionally and personally.   I am truly fortunate to have him as a mentor.  
Thanks to Dr. Edward Scura whose life and cultural lessons, networking 
connections, and boundless knowledge of shrimp farming have been invaluable and have 
shaped my views to a global perspective.    
Additionally, I would like to thank the following individuals from Harrisvaccines 
for helping with so much laboratory work and shrimp care.  Pamela Whitson, Ashley 
Baert, Kristen Summerfelt, Ryan Olive, Katie Schubert, and Katie Stueck for shrimp care 
and animal assistance.  I cannot thank my research assistant Jill Gander and laboratory 
assistants Kay Kimpston-Burkgren, and Kara Burrack enough for all their contributions 
to this work.  
Thank you to Dr. Max Rothschild and Dr. Benny Mote for introducing me to the 
world of research (and PCR!) and giving me a fantastic opportunity as an undergraduate 
student to do great things.  You both inspire me greatly, and the skills I learned in your 
lab gave me the ability to answer the new students when they inevitably ask, “How did 
they extract DNA before Qiagen kits?”  
I would like to thank all my classmates, friends and family for their continued 
support.  Thank you to the CVM class of 2009 for a great four years and a network of 
extraordinary individuals.  Thank you to my parents Dan and Laurie Loy and all four of 
my wonderful grandparents, for their continued support, guidance, assistance, and 
 113 
patience for over a decade of higher education.  I could not have gotten this far without 
your support and guidance.   
Lastly, and most importantly, I would like to thank my wife, Duan Loy for her 
endless support, assistance, and encouragement.  There is not enough room in the 
dissertation to describe her many contributions to this work, but this would have been an 
impossible task without her, and I am exceedingly lucky and blessed to have such a 
person in my life.     
